[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 141
1. Calcagno DQ, Leal MF, Taken SS, Assumpção PP, Demachki S, Smith Mde A, Burbano RR: Aneuploidy of chromosome 8 and C-MYC amplification in individuals from northern Brazil with gastric adenocarcinoma. Anticancer Res; 2005 Nov-Dec;25(6B):4069-74
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneuploidy of chromosome 8 and C-MYC amplification in individuals from northern Brazil with gastric adenocarcinoma.
  • MATERIALS AND METHODS: Dual-color fluorescence in situ hybridization (FISH) for the C-MYC gene and chromosome 8 centromere was performed in 11 gastric adenocarcinomas.
  • CONCLUSION: Chromosome 8 can be used as a marker in the diagnosis of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Aneuploidy. Chromosomes, Human, Pair 8 / genetics. Genes, myc / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Alleles. Brazil. Gene Amplification. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Lymphocytes / ultrastructure. Male. Middle Aged. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Anticancer Res. 2006 Jan-Feb;26(1a):445
  • (PMID = 16309200.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


2. Lee CH, Bang SH, Lee SK, Song KY, Lee IC: Gene expression profiling reveals sequential changes in gastric tubular adenoma and carcinoma in situ. World J Gastroenterol; 2005 Apr 7;11(13):1937-45
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling reveals sequential changes in gastric tubular adenoma and carcinoma in situ.
  • METHODS: We analyzed the expression profiles of normal gastric pit, tubular adenoma and carcinoma in situ using microdissected cells from routine gastric biopsies.
  • The differential expression between adenoma and carcinoma in situ was subtle: 50 and 22 genes were up-, and down-regulated in carcinomas at the expected false significance rate of 0.61%, respectively.
  • CONCLUSION: Groups of genes are shown to reflect the sequential expression changes in the early carcinogenic steps of stomach cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma in Situ / genetics. Gene Expression Profiling. Stomach Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800983.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4305714
  •  go-up   go-down


3. Calcagno DQ, Guimarães AC, Leal MF, Seabra AD, Khayat AS, Pontes TB, Assumpção PP, De Arruda Cardoso Smith M, Burbano RR: MYC insertions in diffuse-type gastric adenocarcinoma. Anticancer Res; 2009 Jul;29(7):2479-83
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MYC insertions in diffuse-type gastric adenocarcinoma.
  • MATERIALS AND METHODS: MYC copy number and its insertion, as well as the chromosomes in which MYC was inserted, were evaluated by fluorescence in situ hybridization assay in interphase and metaphase cells of 12 diffuse-type gastric cancer samples.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, myc. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. Chromosomes, Human, Pair 8. Gene Dosage. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Interphase. Metaphase. Middle Aged. Trisomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596917.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


Advertisement
4. Ryan JL, Morgan DR, Dominguez RL, Thorne LB, Elmore SH, Mino-Kenudson M, Lauwers GY, Booker JK, Gulley ML: High levels of Epstein-Barr virus DNA in latently infected gastric adenocarcinoma. Lab Invest; 2009 Jan;89(1):80-90
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High levels of Epstein-Barr virus DNA in latently infected gastric adenocarcinoma.
  • Gastric adenocarcinoma is the second leading cause of cancer death worldwide.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 2008;43(6):669-74 [18569983.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Jun;11(2):149-52 [12777999.001]
  • [Cites] Oncol Rep. 2003 Jul-Aug;10(4):1059-62 [12792770.001]
  • [Cites] Gastric Cancer. 2003;6(3):173-8 [14520531.001]
  • [Cites] Clin Infect Dis. 2003 Nov 1;37(9):1244-9 [14557970.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7062-7 [14612496.001]
  • [Cites] J Virol. 2004 Feb;78(4):1893-902 [14747554.001]
  • [Cites] Herpes. 2003 Dec;10(3):78-82 [14759340.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):664-70 [14966089.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1698-705 [15014022.001]
  • [Cites] Indian J Pathol Microbiol. 2003 Jan;46(1):34-6 [15027715.001]
  • [Cites] Gastric Cancer. 2004;7(1):9-16 [15052434.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jul;128(7):765-70 [15214826.001]
  • [Cites] Oncol Rep. 2004 Sep;12(3):543-7 [15289835.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(2-3):87-94 [15361640.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):378-85 [15507678.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):805-9 [8039108.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9131-5 [8090780.001]
  • [Cites] APMIS. 1994 Jul;102(7):495-500 [7917218.001]
  • [Cites] Hum Pathol. 1996 Jan;27(1):20-7 [8543306.001]
  • [Cites] Br J Cancer. 1996 Aug;74(4):625-31 [8761381.001]
  • [Cites] Int J Cancer. 1997 Apr 10;71(2):155-8 [9139835.001]
  • [Cites] Pathol Int. 1997 Oct;47(10):730-4 [9361110.001]
  • [Cites] J Pathol. 1997 Nov;183(3):293-8 [9422984.001]
  • [Cites] Arch Virol. 1997;142(9):1743-56 [9672634.001]
  • [Cites] Int J Mol Med. 1998 Jan;1(1):137-42 [9852211.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):941-7 [10487851.001]
  • [Cites] J Virol. 2004 Dec;78(24):13470-8 [15564458.001]
  • [Cites] World J Gastroenterol. 2005 Jan 7;11(1):27-30 [15609391.001]
  • [Cites] J Virol. 2005 Jan;79(2):1296-307 [15613356.001]
  • [Cites] World J Gastroenterol. 2005 Feb 7;11(5):629-33 [15655811.001]
  • [Cites] World J Gastroenterol. 2005 Jun 7;11(21):3234-9 [15929173.001]
  • [Cites] J Virol. 2005 Nov;79(22):13984-92 [16254334.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):288-97 [16247482.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2689-94 [16477006.001]
  • [Cites] Methods Mol Biol. 2006;326:115-37 [16780197.001]
  • [Cites] J Pathol. 2006 Aug;209(4):430-5 [16710842.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Sep;4(9):1103-11 [16820326.001]
  • [Cites] Expert Opin Biol Ther. 2006 Nov;6(11):1193-205 [17049016.001]
  • [Cites] J Mol Diagn. 2008 Jul;10(4):279-92 [18556771.001]
  • [Cites] Korean J Intern Med. 2004 Mar;19(1):43-7 [15053043.001]
  • [Cites] J Clin Pathol. 2004 May;57(5):487-91 [15113855.001]
  • [Cites] J Virol. 1999 Dec;73(12):10525-30 [10559372.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):45-50 [10665912.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):1-10 [11227065.001]
  • [Cites] Eur J Cancer Prev. 2001 Feb;10(1):69-75 [11263593.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1856-9 [11448896.001]
  • [Cites] Intern Med J. 2001 Jul;31(5):296-303 [11512601.001]
  • [Cites] Microsc Res Tech. 2001 Jun 15;53(6):409-13 [11525258.001]
  • [Cites] Int J Cancer. 2001 Nov15;94(4):527-30 [11745439.001]
  • [Cites] J Med Virol. 2002 Mar;66(3):351-9 [11793387.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):781-6 [11891176.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1920-6 [11912175.001]
  • [Cites] Mod Pathol. 2002 Aug;15(8):870-7 [12181273.001]
  • [Cites] Scand J Gastroenterol. 2002 Jul;37(7):825-9 [12190097.001]
  • [Cites] J Clin Pathol. 2002 Sep;55(9):669-75 [12194996.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4876-8 [12208733.001]
  • [Cites] J Pathol. 2002 Aug;197(5):684-8 [12210090.001]
  • [Cites] Diagn Mol Pathol. 2002 Sep;11(3):127-34 [12218450.001]
  • [Cites] J Virol. 2002 Nov;76(21):10951-9 [12368338.001]
  • [Cites] Int J Mol Med. 2002 Nov;10(5):635-9 [12373307.001]
  • [Cites] Neoplasma. 2003;50(1):8-12 [12687272.001]
  • [Cites] Blood. 2006 Nov 1;108(9):2942-9 [16835376.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1358-64 [17873116.001]
  • [Cites] Trans Am Clin Climatol Assoc. 2006;117:55-73; discussion 73-4 [18528464.001]
  • (PMID = 19002111.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / K12 RR1667; United States / NIEHS NIH HHS / ES / ES007017-34; United States / NIDDK NIH HHS / DK / P30 DK034987; United States / NIDDK NIH HHS / DK / P30 DK 034987; United States / NIEHS NIH HHS / ES / T32 ES007017; United States / NIEHS NIH HHS / ES / T32-ES07017; United States / NIEHS NIH HHS / ES / T32 ES007017-34
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Protein Isoforms; 0 / Viral Matrix Proteins
  • [Other-IDs] NLM/ NIHMS68618; NLM/ PMC2612099
  •  go-up   go-down


5. Zhao WH, Wang SF, Ding W, Sheng JM, Ma ZM, Teng LS, Wang M, Wu FS, Luo B: Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action. World J Gastroenterol; 2006 Mar 7;12(9):1356-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action.
  • AIM: To study the apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action.
  • Fas/FasL,PD-ECGF and PCNA were examined by immunohistochemistry and apoptotic tumor cells were detected by in situ TUNEL method.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / pharmacology. Antimetabolites, Antineoplastic / therapeutic use. Apoptosis / drug effects. Floxuridine / pharmacology. Floxuridine / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5C):4363-7 [10650777.001]
  • [Cites] Virchows Arch. 2000 Jul;437(1):31-6 [10963377.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(20):7826-37 [11003676.001]
  • [Cites] Gan To Kagaku Ryoho. 2000 Sep;27(10):1521-6 [11015996.001]
  • [Cites] Cell Res. 2000 Sep;10(3):233-42 [11032175.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Jan;127(1):20-6 [11206267.001]
  • [Cites] Cancer Lett. 2001 May 10;166(1):103-11 [11295293.001]
  • [Cites] Int J Oncol. 2001 Jun;18(6):1157-62 [11351245.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2000 May;22(3):222-4 [11778236.001]
  • [Cites] Cell Death Differ. 2002 Apr;9(4):431-8 [11965496.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2002 Jan;24(1):4-8 [11977635.001]
  • [Cites] Hepatogastroenterology. 2002 May-Jun;49(45):882-6 [12064013.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2002 Jul;24(4):360-3 [12408764.001]
  • [Cites] Cancer. 1996 Apr 15;77(8 Suppl):1628-33 [8608554.001]
  • [Cites] J Surg Oncol. 1997 Jun;65(2):106-10 [9209521.001]
  • [Cites] Gan To Kagaku Ryoho. 1997 Oct;24(13):1947-52 [9350241.001]
  • [Cites] Gan To Kagaku Ryoho. 1998 Feb;25(3):359-64 [9492829.001]
  • [Cites] Mol Pharmacol. 1998 May;53(5):819-26 [9584207.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1305-8 [9721089.001]
  • [Cites] Gan To Kagaku Ryoho. 1999 Feb;26(3):321-7 [10065095.001]
  • [Cites] Jpn J Cancer Res. 1998 Dec;89(12):1334-42 [10081495.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1145-50 [10098749.001]
  • [Cites] Oncology. 1999 Apr;56(3):215-22 [10202277.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1911-6 [10213500.001]
  • [Cites] Anticancer Res. 2002 Sep-Oct;22(5):2607-12 [12529971.001]
  • [Cites] Oncol Rep. 2003 Jan-Feb;10(1):115-9 [12469155.001]
  • [Cites] World J Gastroenterol. 2003 Mar;9(3):442-5 [12632493.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):660-4 [12679905.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):717-20 [12679918.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2003 Jan;25(1):66-9 [12678992.001]
  • [Cites] Kongressbd Dtsch Ges Chir Kongr. 2002;119:396-7 [12704896.001]
  • [Cites] Br J Cancer. 2003 Jun 2;88(11):1800-7 [12771998.001]
  • [Cites] World J Gastroenterol. 2003 Jul;9(7):1415-20 [12854132.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2003 Aug;32(4):347-9 [14514381.001]
  • [Cites] Surg Today. 2003;33(11):847-53 [14605957.001]
  • [Cites] World J Gastroenterol. 2004 Feb 1;10(3):348-51 [14760755.001]
  • [Cites] World J Gastroenterol. 2004 Feb 15;10(4):484-90 [14966903.001]
  • [Cites] World J Gastroenterol. 2004 Mar 15;10(6):804-8 [15040021.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2004 Jan;26(1):4-9 [15059341.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1233-9 [15138561.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2174-8 [15259060.001]
  • [Cites] World J Gastroenterol. 2004 Oct 1;10(19):2911-5 [15334700.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):2053-62 [2680049.001]
  • [Cites] Cancer. 1991 Oct 1;68(7):1501-6 [1893349.001]
  • [Cites] Cancer. 1992 Sep 1;70(5):1030-7 [1515980.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 17;85(22):1839-44 [8230264.001]
  • [Cites] World J Surg. 1995 Jul-Aug;19(4):509-16 [7676692.001]
  • (PMID = 16552801.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Apoptosis Regulatory Proteins; 0 / FAIM protein, human; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Necrosis Factors; 039LU44I5M / Floxuridine; EC 2.4.2.4 / Thymidine Phosphorylase; V1JK16Y2JP / doxifluridine
  • [Other-IDs] NLM/ PMC4124310
  •  go-up   go-down


6. Lo YC, Yang YC, Wu IC, Kuo FC, Liu CM, Wang HW, Kuo CH, Wu JY, Wu DC: Capsaicin-induced cell death in a human gastric adenocarcinoma cell line. World J Gastroenterol; 2005 Oct 28;11(40):6254-7
Hazardous Substances Data Bank. CAPSAICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capsaicin-induced cell death in a human gastric adenocarcinoma cell line.
  • Cell death induced by the binding of capsaicin was examined in a human gastric adenocarcinoma cell line (AGS cells).
  • [MeSH-major] Adenocarcinoma. Capsaicin / pharmacology. Cell Death / drug effects. Stomach Neoplasms
  • [MeSH-minor] Cell Line, Tumor. DNA Fragmentation. Humans. In Situ Nick-End Labeling. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16419151.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; S07O44R1ZM / Capsaicin
  • [Other-IDs] NLM/ PMC4320326
  •  go-up   go-down


7. Kumashiro Y, Yao T, Aishima S, Hirahashi M, Nishiyama K, Yamada T, Takayanagi R, Tsuneyoshi M: Hepatoid adenocarcinoma of the stomach: histogenesis and progression in association with intestinal phenotype. Hum Pathol; 2007 Jun;38(6):857-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid adenocarcinoma of the stomach: histogenesis and progression in association with intestinal phenotype.
  • Hepatoid adenocarcinoma is an extrahepatic tumor characterized by morphological similarities to hepatocellular carcinoma.
  • The lesions contain a tubular adenocarcinoma that seems to develop "hepatoid" features, but the relation between the tubular adenocarcinomatous and the hepatoid components remains unclear.
  • We compared the cellular phenotypes of 23 cases of hepatoid adenocarcinoma of the stomach having tubular adenocarcinomatous components with 69 cases of non-hepatoid adenocarcinoma of the stomach.
  • Afterward, we examined the expression of CDX2 and p53 in the tubular adenocarcinomatous and hepatoid components of hepatoid adenocarcinoma.
  • Both components of hepatoid adenocarcinoma were classified into 4 phenotypic categories according to the immunohistochemical results for CD10, MUC2, MUC5AC, and MUC6.
  • In contrast, no gastric phenotype (MUC5AC+, MUC6+, MUC2-, CD10-) was observed in any of the hepatoid adenocarcinoma components.
  • These findings suggest that hepatoid adenocarcinoma arises from an adenocarcinoma with an intestinal phenotype and that its hepatoid component is in some way related to reduced CDX2 expression.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Homeodomain Proteins / biosynthesis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Aged. Albumins / metabolism. Disease Progression. Humans. Immunohistochemistry. In Situ Hybridization. Intestinal Mucosa / pathology. Liver Neoplasms / pathology. Middle Aged. Mucin-2. Mucin-6. Mucins / metabolism. Neprilysin / metabolism. Phenotype. RNA, Messenger / analysis. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320150.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Albumins; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / MUC6 protein, human; 0 / Mucin-2; 0 / Mucin-6; 0 / Mucins; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; 0 / alpha-Fetoproteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


8. Assumpção PP, Ishak G, Chen ES, Takeno SS, Leal MF, Guimarães AC, Calcagno DQ, Khayat AS, Demachki S, Smith Mde A, Burbano RR: Numerical aberrations of chromosome 8 detected by conventional cytogenetics and fluorescence in situ hybridization in individuals from northern Brazil with gastric adenocarcinoma. Cancer Genet Cytogenet; 2006 Aug;169(1):45-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Numerical aberrations of chromosome 8 detected by conventional cytogenetics and fluorescence in situ hybridization in individuals from northern Brazil with gastric adenocarcinoma.
  • In northern Brazil, the state of Pará shows a high incidence of this disease and the capital ranks among cities with the highest incidence of stomach cancer in the world.
  • To evaluate chromosomal aberrations implicated in gastric carcinogenesis, we analyzed 16 samples of gastric adenocarcinoma by fluorescence in situ hybridization using a chromosome 8 alpha-satellite probe and by direct chromosomal analysis techniques.
  • There was no significant difference between chromosome 8 ploidy and localization, stage, or histological type of adenocarcinoma in our sample.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 8. In Situ Hybridization, Fluorescence. Stomach Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875936.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Costa Guimarães A, Gonçalves Quintana L, Ferreira Leal M, Satomi Takeno S, Pimentel Assumpção P, Moura Lima E, Salim Khayat A, Suchi Chen E, de Arruda Cardoso Smith M, Rodríguez Burbano R: Aneuploidy of chromosome 8 detected by fluorescence in situ hybridisation in ACP01 cell line gastric adenocarcinoma. Clin Exp Med; 2006 Oct;6(3):129-33
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneuploidy of chromosome 8 detected by fluorescence in situ hybridisation in ACP01 cell line gastric adenocarcinoma.
  • ACP01 is the first gastric adenocarcinoma cell line developed in Brazil.
  • To evaluate chromosomal aberrations implicated in gastric carcinogenesis, we analysed three different passages (6th, 12th and 35th) of ACP01 cell line by fluorescence in situ hybridisation using chromosome 8 alpha-satellite probe.
  • Our results confirm that trisomy of chromosome 8 is a common biological phenomenon in adenocarcinoma of stomach and can be used as a gastric mucosa malignancy marker.
  • It is, therefore, necessary to conduct new studies aiming to identify peculiar genetic characteristics of a tumour, which might help in diagnosis and prognosis of this disease, besides allowing more accurate therapeutic conduct to be established.
  • [MeSH-major] Adenocarcinoma / genetics. Aneuploidy. Chromosomes, Human, Pair 8 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Humans. In Situ Hybridization, Fluorescence. Trisomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17061062.001).
  • [ISSN] 1591-8890
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


10. Supriatna Y, Kishimoto T, Uno T, Nagai Y, Ishikura H: Evidence for hepatocellular differentiation in alpha-fetoprotein-negative gastric adenocarcinoma with hepatoid morphology: a study with in situ hybridisation for albumin mRNA. Pathology; 2005 Jun;37(3):211-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for hepatocellular differentiation in alpha-fetoprotein-negative gastric adenocarcinoma with hepatoid morphology: a study with in situ hybridisation for albumin mRNA.
  • AIM: Hepatoid adenocarcinoma, a putative chemosensitive tumour, is defined as a tumour with aberrant hepatocellular differentiation occurring in extrahepatic organs such as the stomach, usually in the gastrointestinal tract.
  • We investigated ALB mRNA to address whether adenocarcinoma with hepatoid morphology, regardless of AFP production, can be diagnosed solely by morphological criteria as a hepatoid adenocarcinoma.
  • METHODS: We performed in situ hybridisation (ISH) and immunohistochemistry (IH) for ALB mRNA on AFP-negative gastric adenocarcinomas with hepatoid morphology.
  • Three of five cases of AFP-positive hepatoid adenocarcinoma of the stomach were positive for ALB mRNA, while 11 cases of AFP-negative conventional gastric adenocarcinoma were negative.
  • CONCLUSION: The present study demonstrates that, irrespective of AFP production, gastric adenocarcinoma with morphological patterns suggestive of hepatoid differentiation should be diagnosed as hepatoid adenocarcinoma with important prognostic implications.
  • [MeSH-major] Adenocarcinoma / pathology. Albumins / biosynthesis. Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / pathology. Stomach Neoplasms / pathology. alpha-Fetoproteins / biosynthesis
  • [MeSH-minor] Diagnosis, Differential. Hepatocytes / pathology. Humans. Immunohistochemistry. In Situ Hybridization. RNA, Messenger / analysis. RNA, Neoplasm / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175893.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Albumins; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / alpha-Fetoproteins
  •  go-up   go-down


11. Hirano N, Tsukamoto T, Mizoshita T, Koriyama C, Akiba S, Campos F, Carrasquilla G, Carrascal E, Cao X, Toyoda T, Ban H, Miki K, Tatematsu M: Down regulation of gastric and intestinal phenotypic expression in Epstein-Barr virus-associated stomach cancers. Histol Histopathol; 2007 06;22(6):641-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down regulation of gastric and intestinal phenotypic expression in Epstein-Barr virus-associated stomach cancers.
  • AIMS: We have previously demonstrated the importance of gastric and intestinal phenotypic expression for stomach carcinogenesis.
  • In this study, we focused on Epstein-Barr virus (EBV)-associated stomach cancers, with special attention to Cdx2.
  • METHODS AND RESULTS: We evaluated the expression of gastric and intestinal phenotypic markers by immunohistochemistry in 35 EBV-positive [EBV (+)] and 75 EBV-negative [EBV (-)] stomach cancers in Colombia.
  • The expression of Cdx2 and MUC2 was also found to be significantly lower in EBV (+) than in EBV (-) stomach cancers (P=0.0001; P<0.0001).
  • CONCLUSIONS: EBV (+) stomach cancers are characterized by low expression of intestinal phenotype markers, including Cdx2, and only occasional gastric phenotypic expression.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / virology. Biomarkers, Tumor / analysis. Epstein-Barr Virus Infections / metabolism. Stomach Neoplasms / metabolism. Stomach Neoplasms / virology
  • [MeSH-minor] CDX2 Transcription Factor. Down-Regulation. Female. Herpesvirus 4, Human. Homeodomain Proteins / metabolism. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Mucin-2. Mucins / metabolism. Phenotype. RNA, Viral / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357094.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / Epstein-Barr virus encoded RNA 1; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins; 0 / RNA, Viral
  •  go-up   go-down


12. Zhang L, Sanderson SO, Lloyd RV, Smyrk TC: Pancreatic intraepithelial neoplasia in heterotopic pancreas: evidence for the progression model of pancreatic ductal adenocarcinoma. Am J Surg Pathol; 2007 Aug;31(8):1191-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic intraepithelial neoplasia in heterotopic pancreas: evidence for the progression model of pancreatic ductal adenocarcinoma.
  • Morphologic, clinical, and genetic evidence suggests that pancreatic intraepithelial neoplasia (PanIN) is a precursor to ductal adenocarcinoma.
  • The presence of PanIN in heterotopic pancreas from patients with ductal adenocarcinoma supports the progression model.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Choristoma / pathology. Duodenal Diseases / pathology. Pancreas. Pancreatic Neoplasms / pathology. Stomach Diseases / pathology


13. Ftériche F, Bouzid T, Makni A, Ksantini R, Bdioui H, Chebbi F, Jouini M, Ammous A, Kacem M, Ben Safta Z: [Gastric adenocarcinoma with lymphoid stroma. About nine cases]. Tunis Med; 2007 Aug;85(8):688-91
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma with lymphoid stroma. About nine cases].
  • The tumor was in the antrum in 4 cases, in the body of the stomach in 3 cases and in the cardia in 2 cases.
  • The mean tumor size was 8 cm with deep invasion of the stomach wall in 5 cases and ganglionnary invasion in 6 cases out of 9.
  • EBV was detected in all patients by in situ hybridation.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18254293.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


14. Anwar M, Koriyama C, Naveed IA, Hamid S, Ahmad M, Itoh T, Minakami Y, Eizuru Y, Akiba S: Epstein-barr virus detection in tumors of upper gastrointestinal tract. An in situ hybridization study in Pakistan. J Exp Clin Cancer Res; 2005 Sep;24(3):379-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-barr virus detection in tumors of upper gastrointestinal tract. An in situ hybridization study in Pakistan.
  • To examine the potential role of Epstein-Barr virus (EBV) in the carcinogenesis of upper gastrointestinal tract, we conducted an in situ hybridization assay for EBV-encoded small RNA (EBER) expression in the tumors of 56 oral and 50 esophageal squamous cell carcinoma (SCC) cases, and 52 stomach adenocarcinoma cases diagnosed in the King Edward Medical College and Allama Iqbal Medical College Lahore, Pakistan between 1996-2002.
  • Only one out of the 52 gastric adenocarcinoma cases (1.9%) was positive for EBER expression, and this frequency was relatively low as compared to cases reported worldwide.
  • The case was a 42 year-old male patient and histologically classified as moderately differentiated tubular adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Squamous Cell / virology. Gastrointestinal Neoplasms / virology. Herpesvirus 4, Human / isolation & purification
  • [MeSH-minor] Adult. Base Sequence. DNA Probes. Female. Humans. In Situ Hybridization. Male. Middle Aged. Pakistan

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270524.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / DNA Probes
  •  go-up   go-down


15. Wang GQ, Wei WQ, Zhang JH: [Natural progression of early stage adenocarcinoma of gastric cardia: a report of seventeen cases]. Ai Zheng; 2007 Nov;26(11):1153-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Natural progression of early stage adenocarcinoma of gastric cardia: a report of seventeen cases].
  • BACKGROUND & OBJECTIVE: The survival time of untreated advanced gastric cardiac adenocarcinoma patients is about 8-9 months.
  • This study was to observe the natural progression of untreated early stage gastric cardiac adenocarcinoma.
  • METHODS: In 1987, at a high risk area of esophageal cancer, 851 patients with a previous cytologic diagnosis of esophageal dysplasia were re-examined by endoscopy, and 43 of them were diagnosed histologically as gastric cardiac adenocarcinoma.
  • RESULTS: Of the 17 untreated patients, 12 were died of gastric cardiac adenocarcinoma, 5 were died of non-cancer diseases; 13 had survived for over 5 years.
  • CONCLUSIONS: The progression of early stage cardiac cancer to advanced cancer is a very slow and long process, which is very helpful for early diagnosis and choice of therapeutic timing.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Disease Progression. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma in Situ / pathology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991310.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


16. Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A: Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol; 2006 Oct;37(10):1333-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
  • In a combined analysis of immunohistochemistry and fluorescence in situ hybridization on 552 formalin-fixed and paraffin-embedded gastric cancer tissues, 38 cases were found to have HER2 amplification.
  • Further examination by fluorescence in situ hybridization revealed amplification of TOP2A in 13 of the 38 cases.
  • Fluorescence in situ hybridization was performed on nuclear imprint specimens obtained from 9 cases using simultaneous probes for TOP2A, HER2, and centromere 17.
  • Although patients having gastric adenocarcinoma with TOP2A amplification could be considered suitable for clinical trials, information involving anthracycline therapy is not firmly understood in regards to the status of TOP2A amplification or protein overexpression.
  • [MeSH-major] Adenocarcinoma / enzymology. Antigens, Neoplasm / genetics. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Gene Amplification. Genes, erbB-2. Stomach Neoplasms / enzymology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Blotting, Western. DNA, Neoplasm / analysis. Female. Gene Dosage. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence / methods. Male. Middle Aged. Neoplasm Staging. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949920.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


17. Zhang J, Fu YC, Kang CS, Zhang QY, Wang T, Zhang J: [Inhibitory effect of adenovirus-mediated short hairpin RNA targeting P85 and Akt1 on growth of human gastric adenocarcinoma cell]. Zhonghua Nei Ke Za Zhi; 2009 Jul;48(7):557-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inhibitory effect of adenovirus-mediated short hairpin RNA targeting P85 and Akt1 on growth of human gastric adenocarcinoma cell].
  • OBJECTIVE: To construct a short hairpin RNA(shRNA) adenovirus vector targeting P85 and protein kinase B1 (PKB1/Akt1) and study its effects on the growth of SGC-7901 human gastric adenocarcinoma cells.
  • The proliferative activity of tumor cells was evaluated with MTT assay and flow cytometry in vitro. rAd5-HK and rAd5-P + A mediated by adenovirus were injected into the established subcutaneous SGC-7901 gastric adenocarcinoma in nude mice.
  • During the observation period of 21 days, tumor volume was measured every 3 days to further testify the anti-tumor effect of rAd5-P + A on the SGC-7901 gastric adenocarcinoma cells and cell in situ apoptosis was detected with TUNEL assay.
  • RESULTS: The adenovirus vector rAd5-P + A was successfully constructed and it dramatically downregulated P85 and Akt1 mRNA expression in SGC-7901 gastric adenocarcinoma cells.
  • Moreover, rAd5-P + A could induce cell in situ apoptosis.
  • CONCLUSIONS: Adenovirus-mediated targeting P85 and Akt1 shRNA can inhibit the growth of SGC-7901 human gastric adenocarcinoma cells and this may provide a new strategy of combination gene therapy in gastric adenocarcinoma.
  • [MeSH-major] Proto-Oncogene Proteins c-akt / genetics. RNA, Small Interfering. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957795.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


18. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA: Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res; 2005 May 15;11(10):3766-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm.
  • PURPOSE: Patients with metastatic adenocarcinoma of unknown origin are a common clinical problem.
  • In the first (training) round, we studied 352 primary adenocarcinomas, from seven main sites (breast, colon, lung, ovary, pancreas, prostate and stomach) and their differential diagnoses.
  • CONCLUSIONS: This classification scheme should enable better prediction on biopsy material of the primary site in patients with metastatic adenocarcinoma of unknown origin, leading to improved management and therapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization. Predictive Value of Tests. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897574.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


19. Papaziogas B, Koutelidakis I, Tsiaousis P, Panagiotopoulou K, Paraskevas G, Argiriadou H, Atmatzidis S, Atmatzidis K: Carcinoma developing in ectopic pancreatic tissue in the stomach: a case report. Cases J; 2008;1(1):249

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma developing in ectopic pancreatic tissue in the stomach: a case report.
  • Microscopically, an endoepithelial (in situ) carcinoma of the gastric antrum was determined, which in places turned into an microinvasive endomucosal adenocarcinoma.
  • It also incidentally demonstrated heterotopic pancreatic ducts, detected within the mucosa to the muscularis propria of the same region of the stomach, in which an endoepithelial (in situ) carcinoma was evolving.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Z Gastroenterol. 1995 May;33(5):260-4 [7610694.001]
  • [Cites] Histopathology. 1992 May;20(5):433-5 [1587493.001]
  • [Cites] J Pediatr Surg. 1991 Nov;26(11):1289-92 [1812259.001]
  • [Cites] Gastrointest Endosc. 1991 Mar-Apr;37(2):196-8 [2032610.001]
  • [Cites] Postgrad Med J. 1988 Oct;64(756):801-3 [3255924.001]
  • [Cites] Am J Gastroenterol. 1990 May;85(5):597-601 [2337064.001]
  • [Cites] Arch Pathol Lab Med. 2000 Aug;124(8):1196-200 [10923083.001]
  • [Cites] J Pediatr Surg. 1977 Aug;12(4):593-9 [894461.001]
  • [Cites] Can J Surg. 1976 Sep;19(5):413-4 [974927.001]
  • [Cites] Arch Surg. 1974 Dec;109(6):762-5 [4420439.001]
  • [Cites] J Korean Med Sci. 2004 Feb;19(1):145-8 [14966359.001]
  • [Cites] Can J Surg. 2001 Dec;44(6):407 [11764870.001]
  • [Cites] Pathol Int. 2001 Jul;51(7):549-54 [11472568.001]
  • [Cites] West J Med. 1981 Jul;135(1):57-62 [7257381.001]
  • (PMID = 18928565.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2577107
  •  go-up   go-down


20. Kobayashi M, Lee H, Schaffer L, Gilmartin TJ, Head SR, Takaishi S, Wang TC, Nakayama J, Fukuda M: A distinctive set of genes is upregulated during the inflammation-carcinoma sequence in mouse stomach infected by Helicobacter felis. J Histochem Cytochem; 2007 Mar;55(3):263-74
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A distinctive set of genes is upregulated during the inflammation-carcinoma sequence in mouse stomach infected by Helicobacter felis.
  • In the present study we used insulin-gastrin (INS-GAS) transgenic mice that fully develop gastric adenocarcinoma after infection of H. pylori-related Helicobacter felis.
  • Histological examination revealed that more than half of those mice developed invasive adenocarcinoma after 8 months of infection.
  • Time-course analysis of gene expression by using gene microarray revealed upregulation of several inflammation-associated genes including chemokines, adhesion molecules, surfactant protein D (SP-D), and CD74 in the infected stomach.
  • Immunohistochemical analysis demonstrated that SP-D is expressed in hyperplasia and adenocarcinoma whereas CD74 is expressed in adenocarcinoma in situ and invasive carcinoma.
  • These results as a whole indicate that H. felis induces HEV-like vessels and inflammation-associated chemokines and chemokine receptors, followed by adenocarcinoma formation.
  • [MeSH-major] Adenocarcinoma / metabolism. Gastritis / metabolism. Gene Expression Profiling. Helicobacter Infections / metabolism. Helicobacter felis. Stomach / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101721.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-33000; United States / NCI NIH HHS / CA / CA-71932; United States / NIGMS NIH HHS / GM / GM-62116
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5-acetylneuraminyl-(2-3)-galactosyl-(1-4)-(fucopyranosyl-(1-3))-N-acetylglucosamine; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Gastrins; 0 / Histocompatibility Antigens Class II; 0 / Insulin; 0 / Oligosaccharides; 0 / Pulmonary Surfactant-Associated Protein D; 0 / invariant chain; EC 2.4.- / Glycosyltransferases
  •  go-up   go-down


21. Au WY, Pang A, Chan EC, Chu KM, Shek TW, Kwong YL: Epstein-barr virus-related gastric adenocarcinoma: an early secondary cancer post hemopoietic stem cell transplantation. Gastroenterology; 2005 Dec;129(6):2058-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-barr virus-related gastric adenocarcinoma: an early secondary cancer post hemopoietic stem cell transplantation.
  • METHODS: We studied a case of early onset gastric adenocarcinoma after nonmyeloablative hematopoietic stem cell transplantation for myeloma in a 56-year-old man.
  • RESULTS: The development of gastric adenocarcinoma was preceded by severe graft-versus-host disease (GVHD) necessitating strong immunosuppression, which resulted in an intense reactivation of EBV infection.
  • Three sequential gastric biopsy examinations performed at 100, 130, and 150 days after hematopoietic stem cell transplantation showed gastritis, dysplasia, and adenocarcinoma, respectively.
  • In situ hybridization for EBV-encoded early small RNA showed absence of EBV in the gastritis specimen, but the presence of EBV in the dysplastic and carcinoma specimens.
  • [MeSH-major] Adenocarcinoma / etiology. Epstein-Barr Virus Infections / etiology. Hematopoietic Stem Cell Transplantation / adverse effects. Herpesvirus 4, Human. Neoplasms, Second Primary. Stomach Neoplasms / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16344071.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins
  •  go-up   go-down


22. Lu HZ, Wu YP, Luo W, Han YL, Cai Y, Xu X, Liang J, Liu SM, Wang MR: [Correlation between aneuploidy of chromosome 17, over-expression of TP53 and TOPIIalpha, and the clinicopathological features and diagnosis of gastric adenocarcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Oct;31(10):754-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between aneuploidy of chromosome 17, over-expression of TP53 and TOPIIalpha, and the clinicopathological features and diagnosis of gastric adenocarcinoma].
  • OBJECTIVE: The purpose of this study was to investigate the markers which can be used in auxiliary diagnosis of gastric adenocarcinoma (GAC), and their correlation with their clinicopathological features.
  • METHODS: 122 surgical specimens including 99 gastric adenocarcinoma (GAC), 18 adjacent mucosa and 5 distal normal mucosa were collected, and analyzed by in situ hybridization (FISH).
  • CONCLUSION: Detection of aneuploidy of cen17 as well as over-expression of TP53 and TOPIIalpha may be helpful in the diagnosis and prognostic prediction of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Aneuploidy. Antigens, Neoplasm / metabolism. Chromosomes, Human, Pair 17 / genetics. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Stomach Neoplasms. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021828.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


23. Khayat AS, Guimarães AC, Calcagno DQ, Seabra AD, Lima EM, Leal MF, Faria MH, Rabenhorst SH, Assumpção PP, Demachki S, Smith MA, Burbano RR: Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma. BMC Gastroenterol; 2009;9:55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma.
  • BACKGROUND: This study evaluates the existence of numerical alterations of chromosome 17 and TP53 gene deletion in gastric adenocarcinoma.
  • METHODS: Dual-color fluorescence in situ hybridization and immunostaining were performed in twenty gastric cancer samples of individuals from Northern Brazil.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 17 / genetics. Gene Deletion. Gene Expression Regulation, Neoplastic / genetics. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Alleles. Brazil. Breast Neoplasms / genetics. Breast Neoplasms / pathology. Case-Control Studies. Female. Humans. In Situ Hybridization, Fluorescence. Loss of Heterozygosity / genetics. Male. Middle Aged

  • Genetic Alliance. consumer health - Chromosome 17, Deletion.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Sep;37(3):241-9 [10971700.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Apr 1;190(1):1-7 [19264226.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):258-70 [12619111.001]
  • [Cites] Acta Biochim Pol. 2003;50(1):231-8 [12673364.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1311-20 [13679439.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):155-9 [15015591.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Sep;153(2):127-32 [15350302.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1328-37 [15154013.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 May;83(9):2934-8 [3458254.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Aug;22(4):295-307 [3731046.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Jan;24(1):63-73 [3791173.001]
  • [Cites] Histochemistry. 1988;89(4):307-16 [3410743.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):491-7 [2364362.001]
  • [Cites] Virchows Arch. 1995;426(5):447-55 [7633655.001]
  • [Cites] Int J Cancer. 1996 May 29;66(5):594-9 [8647618.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):720-6 [8625172.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4 [8692948.001]
  • [Cites] Am J Pathol. 1996 Nov;149(5):1575-84 [8909247.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Dec;92(2):122-9 [8976368.001]
  • [Cites] Nihon Ika Daigaku Zasshi. 1997 Feb;64(1):22-9 [9119949.001]
  • [Cites] Oncology. 1997 Mar-Apr;54(2):166-70 [9075790.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Apr 1;102(1):88-90 [9530349.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Am J Phys Anthropol. 1999 Jun;109(2):175-80 [10378456.001]
  • [Cites] J Int Med Res. 1999 Mar-Apr;27(2):85-9 [10446695.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2005 Apr;40(4):467-70 [15795596.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 10;331(3):694-700 [15865924.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1759-66 [15827559.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6B):4069-74 [16309200.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Aug;169(1):45-9 [16875936.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):2909-14 [16886612.001]
  • [Cites] World J Gastroenterol. 2006 Oct 14;12(38):6207-11 [17036397.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3139-46 [10955795.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Aug;121(1):38-43 [10958939.001]
  • [Cites] Clin Exp Med. 2006 Oct;6(3):129-33 [17061062.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1154-60 [16855375.001]
  • [Cites] Arq Gastroenterol. 2006 Jul-Sep;43(3):247-51 [17160244.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):13-8 [18091326.001]
  • [Cites] Cancer Lett. 2008 Aug 8;266(2):99-115 [18381231.001]
  • [Cites] Lab Invest. 2000 Oct;80(10):1501-8 [11045566.001]
  • (PMID = 19619279.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2716360
  •  go-up   go-down


24. Callacondo D, Ganoza-Salas A, Anicama-Lima W, Quispe-Mauricio A, Longacre TA: Primary squamous cell carcinoma of the stomach with paraneoplastic leukocytosis: a case report and review of literature. Hum Pathol; 2009 Oct;40(10):1494-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary squamous cell carcinoma of the stomach with paraneoplastic leukocytosis: a case report and review of literature.
  • Apparently pure, primary squamous cell carcinoma of the stomach is exceedingly rare.
  • Immunohistochemical and in situ hybridization studies for human papillomavirus and Epstein-Barr virus were negative.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Leukocytosis / pathology. Paraneoplastic Syndromes / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged, 80 and over. Diabetes Mellitus, Type 2 / complications. Humans. Hypertension / complications. Immunohistochemistry. In Situ Hybridization. Male. Neoplasms, Multiple Primary / pathology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Stomach carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Hum Pathol. 2010 Feb;41(2):307. Callacondo-Riva, David [corrected to Callacondo, David]
  • (PMID = 19467693.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Bancel B, Esteve J, Souquet JC, Toyokuni S, Ohshima H, Pignatelli B: Differences in oxidative stress dependence between gastric adenocarcinoma subtypes. World J Gastroenterol; 2006 Feb 21;12(7):1005-12
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in oxidative stress dependence between gastric adenocarcinoma subtypes.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Oxidative Stress. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / analysis. Carcinoma in Situ / chemistry. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. DNA, Neoplasm / metabolism. Deoxyguanine Nucleotides / analysis. Female. Gastric Mucosa / chemistry. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Proteins / analysis. Nitric Oxide / metabolism. Nitric Oxide Synthase Type II / metabolism. Precancerous Conditions / chemistry. Precancerous Conditions / pathology. Precancerous Conditions / physiopathology. Retrospective Studies. Tyrosine / analogs & derivatives. Tyrosine / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] APMIS. 1993 Apr;101(4):330-6 [7686760.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Sep 30;187(3):1291-7 [1384469.001]
  • [Cites] Int J Cancer. 1994 Sep 15;58(6):825-9 [7523311.001]
  • [Cites] FEBS Lett. 1995 Jan 16;358(1):1-3 [7821417.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):184-90 [10646872.001]
  • [Cites] Cancer Lett. 1999 Nov 15;146(2):173-80 [10656623.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):167-76 [10680883.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1394-400 [10778969.001]
  • [Cites] Prostate. 2000 Jul 1;44(2):144-55 [10881024.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Helicobacter. 2001 Mar;6(1):37-43 [11328364.001]
  • [Cites] Dig Dis Sci. 2001 Apr;46(4):836-44 [11330421.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1325-32 [11350902.001]
  • [Cites] Am J Gastroenterol. 2001 Jun;96(6):1758-66 [11419826.001]
  • [Cites] Cancer Lett. 2001 Oct 30;172(2):177-85 [11566494.001]
  • [Cites] J Clin Gastroenterol. 2001 Nov-Dec;33(5):383-8 [11606854.001]
  • [Cites] World J Gastroenterol. 2002 Aug;8(4):591-5 [12174362.001]
  • [Cites] BMC Cancer. 2002 Apr 29;2:8 [11978184.001]
  • [Cites] Helicobacter. 2002 Dec;7(6):342-8 [12485120.001]
  • [Cites] Eur J Cancer. 2003 Jun;39(9):1296-301 [12763220.001]
  • [Cites] Arch Biochem Biophys. 2003 Sep 1;417(1):3-11 [12921773.001]
  • [Cites] J Clin Pathol. 2003 Sep;56(9):699-702 [12944556.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):806-12 [14984945.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S37-43 [7762738.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1279-82 [8640814.001]
  • [Cites] Am J Surg Pathol. 1996;20 Suppl 1:S8-22 [8694148.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3238-43 [8764115.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1161-81 [8827022.001]
  • [Cites] J Invest Dermatol. 1996 Nov;107(5):733-7 [8875958.001]
  • [Cites] Lab Invest. 1997 Mar;76(3):365-74 [9121119.001]
  • [Cites] FEBS Lett. 1997 Jul 14;411(2-3):157-60 [9271196.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):19633-6 [9289489.001]
  • [Cites] Carcinogenesis. 1997 Sep;18(9):1841-5 [9328184.001]
  • [Cites] Am J Gastroenterol. 1997 Oct;92(10):1853-7 [9382051.001]
  • [Cites] Mutat Res. 1997 Dec;387(3):147-63 [9439711.001]
  • [Cites] Cancer Lett. 1998 Mar 13;125(1-2):61-8 [9566697.001]
  • [Cites] Gut. 1998 Mar;42(3):351-6 [9577340.001]
  • [Cites] Hum Pathol. 1998 Jul;29(7):702-9 [9670827.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2929-34 [9679948.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Feb;12 Suppl 1:25-36 [9701002.001]
  • [Cites] Eur J Cancer Prev. 1998 Dec;7(6):439-47 [9926291.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1411-5 [10389926.001]
  • [Cites] Free Radic Biol Med. 1999 Aug;27(3-4):401-10 [10468215.001]
  • [Cites] Cancer Lett. 1999 Oct 1;144(2):161-7 [10529016.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] World J Gastroenterol. 2004 Jul 1;10(13):1918-22 [15222037.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2232-40 [15259072.001]
  • [Cites] Food Chem Toxicol. 1990 Sep;28(9):647-52 [2272563.001]
  • [Cites] Gut. 1994 Feb;35(2):179-85 [8307467.001]
  • (PMID = 16534838.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA, Neoplasm; 0 / Deoxyguanine Nucleotides; 0 / Neoplasm Proteins; 31C4KY9ESH / Nitric Oxide; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  • [Other-IDs] NLM/ PMC4087889
  •  go-up   go-down


26. Aida J, Izumiyama-Shimomura N, Nakamura K, Ishii A, Ishikawa N, Honma N, Kurabayashi R, Kammori M, Poon SS, Arai T, Takubo K: Telomere length variations in 6 mucosal cell types of gastric tissue observed using a novel quantitative fluorescence in situ hybridization method. Hum Pathol; 2007 Aug;38(8):1192-200
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere length variations in 6 mucosal cell types of gastric tissue observed using a novel quantitative fluorescence in situ hybridization method.
  • We developed a novel method for evaluating telomere length in 6 cell types of noncancerous and cancerous mucosal tissues from 11 cases of gastric neoplasm using the quantitative fluorescence in situ hybridization method with telomere and centromere peptide nucleic acid probes.
  • [MeSH-major] Adenocarcinoma / metabolism. Gastric Mucosa / metabolism. In Situ Hybridization, Fluorescence. Stomach Neoplasms / metabolism. Telomere / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17588641.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Oligonucleotide Probes; 0 / Peptide Nucleic Acids
  •  go-up   go-down


27. Miskad UA, Semba S, Kato H, Matsukawa Y, Kodama Y, Mizuuchi E, Maeda N, Yanagihara K, Yokozaki H: High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study. Virchows Arch; 2007 Mar;450(3):303-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
  • Levels of PRL-3 expression in 94 human gastric adenocarcinomas and 54 matched lymph node metastases were detected by in situ hybridization and compared with clinicopathological characteristics including prognosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. In Situ Hybridization / methods. Neoplasm Proteins / metabolism. Protein Tyrosine Phosphatases / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17235563.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


28. Shen KR, Cassivi SD, Deschamps C, Allen MS, Nichols FC 3rd, Harmsen WS, Pairolero PC: Surgical treatment of tumors of the proximal stomach with involvement of the distal esophagus: a 26-year experience with Siewert type III tumors. J Thorac Cardiovasc Surg; 2006 Oct;132(4):755-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of tumors of the proximal stomach with involvement of the distal esophagus: a 26-year experience with Siewert type III tumors.
  • OBJECTIVE: A paucity of outcome data exists regarding patients with proximal stomach cancer involving the distal esophagus (Siewert type III tumors).
  • Pathologic stage was 0 (carcinoma in situ) in 1 patient, IB in 13 patients, II in 17 patients, IIIA in 34 patients, IIIB in 10 patients, and IV in 41 patients.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy. Gastrectomy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000284.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Zhang J, Fu YC, Kang CS, Zhang QY, Wang T, Zhang J: [Inhibitory effects of targeting protein kinase B1 and cyclooxygenase-2 shRNA upon human gastric adenocarcinoma cell growth]. Zhonghua Yi Xue Za Zhi; 2009 Aug 25;89(32):2292-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inhibitory effects of targeting protein kinase B1 and cyclooxygenase-2 shRNA upon human gastric adenocarcinoma cell growth].
  • OBJECTIVE: To construct a short hairpin RNA (shRNA) adenovirus vector targeting Akt1 (protein kinase B1, PKB1/Akt1) and cyclooxygenase-2 (COX-2) and study its effects on the growth of SGC-7901 human gastric adenocarcinoma cell.
  • The proliferative activity of tumor cell was evaluated by MTT assay and flow cytometry in vitro. rAd5-HK and rAd5-A + C were injected into the established subcutaneous SGC-7901 gastric adenocarcinoma in nude mice.
  • During the observation period of 21 days, tumor volume was measured every 3 days to further observe the anti-tumor effects of rAd5-A + C on SGC-7901 cell and cell situ apoptosis was detected by TUNEL assay.
  • CONCLUSION: Adenovirus-mediated Akt1 and COX-2 shRNA can inhibit the growth of SGC-7901 human gastric adenocarcinoma cell.
  • [MeSH-major] Cyclooxygenase 2 / genetics. RNA, Small Interfering / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20095346.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Small Interfering; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


30. Levy MJ, Clain JE, Clayton A, Halling KC, Kipp BR, Rajan E, Roberts LR, Root RM, Sebo TJ, Topazian MD, Wang KK, Wiersema MJ, Gores GJ: Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA. Gastrointest Endosc; 2007 Sep;66(3):483-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA.
  • BACKGROUND: Studies indicate enhanced diagnostic accuracy for digital image analysis (DIA) and fluorescence in situ hybridization (FISH) versus routine cytology examination (RC) when biliary strictures are evaluated.
  • The final diagnosis was based on strict cytopathologic and imaging criteria and 12-month follow-up.
  • RESULTS: Malignancy was diagnosed in 30 of 42 patients, including esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, pancreatic mucinous cystic neoplasia, intraductal papillary mucinous neoplasia, metastatic forearm sarcoma, small cell and non-small cell lung cancer, thyroid carcinoma, malignant GI stromal tumor, melanoma, adenocarcinoma of unknown primary, and lymphoma.
  • [MeSH-major] Biopsy, Fine-Needle. Endosonography. Esophageal Neoplasms / pathology. Image Processing, Computer-Assisted. In Situ Hybridization, Fluorescence. Lymphatic Metastasis / pathology. Pancreatic Neoplasms / pathology. Stomach Neoplasms / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Esophagus / pathology. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pancreas / pathology. Pilot Projects. Sensitivity and Specificity. Stomach / pathology


31. Costa Raiol LC, Figueira Silva EC, Mendes da Fonseca D, Leal MF, Guimarães AC, Calcagno DQ, Khayat AS, Assumpção PP, de Arruda Cardoso Smith M, Burbano RR: Interrelationship between MYC gene numerical aberrations and protein expression in individuals from northern Brazil with early gastric adenocarcinoma. Cancer Genet Cytogenet; 2008 Feb;181(1):31-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interrelationship between MYC gene numerical aberrations and protein expression in individuals from northern Brazil with early gastric adenocarcinoma.
  • Early gastric cancer represents approximately 10% of gastric cancer cases in some services of Brazil, which underscores the need for early gastric cancer diagnosis that could lead to better prognosis.
  • To evaluate MYC copy number and its protein expression, we performed fluorescence in situ hybridization and immunohistochemical analyses in five early gastric adenocarcinomas in individuals from northern Brazil.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Genes, myc. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Brazil. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18262050.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Guimarães AC, Lima EM, Khayat AS, Girão Faria MH, Barem Rabenhorst SH, Pitombeira MV, Assumpção PP, de Oliveira Bahia M, Lima de Lima PD, de Arruda Cardoso Smith M, Burbano RR: Interrelationships among chromosome aneuploidy, promoter hypermethylation, and protein expression of the CDKN2A gene in individuals from northern Brazil with gastric adenocarcinoma. Cancer Genet Cytogenet; 2007 Nov;179(1):45-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interrelationships among chromosome aneuploidy, promoter hypermethylation, and protein expression of the CDKN2A gene in individuals from northern Brazil with gastric adenocarcinoma.
  • Fluorescence in situ hybridization analysis with centromeric DNA probes, immunohistochemical staining, and methylation-specific polymerase chain reaction assays were performed in 15 gastric adenocarcinomas samples from individuals from northern Brazil.
  • [MeSH-major] Adenocarcinoma / genetics. Aneuploidy. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Methylation. Genes, p16. Promoter Regions, Genetic. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 9. Chromosomes, Human, X. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17981214.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


33. Liang Z, Zeng X, Gao J, Wu S, Wang P, Shi X, Zhang J, Liu T: Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer; 2008;8:363
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.
  • METHODS: One hundred cases of formalin fixed and paraffin embedded tumor tissues from Chinese gastric carcinoma patients were investigated by immunohistochemistry and fluorescence in situ hybridization (FISH) methods.
  • [MeSH-major] Adenocarcinoma / genetics. Aneuploidy. Antigens, Neoplasm / metabolism. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Receptor, Epidermal Growth Factor / metabolism. Stomach Neoplasms / genetics
  • [MeSH-minor] China. Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 7. Female. Gene Dosage. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Staging. Receptor, ErbB-2 / genetics. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Mar;156(3):839-47 [10702400.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1162-7 [17487844.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8887-95 [11751413.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • [Cites] Mod Pathol. 2002 Feb;15(2):137-45 [11850542.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):833-7 [11948459.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2625-9 [11980659.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6255-63 [12214266.001]
  • [Cites] Leukemia. 2003 Mar;17(3):532-40 [12646941.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):234-41 [12679307.001]
  • [Cites] Cancer. 2003 Aug 25;99(4):233-9 [12925985.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] Int J Cancer. 2003 Dec 10;107(5):764-72 [14566826.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):136-43 [14734462.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):548-53 [14991576.001]
  • [Cites] Cancer Res. 1989 Apr 15;49(8):2087-90 [2564806.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):533-42 [8630962.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1265-73 [15712203.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Breast J. 2005 Nov-Dec;11(6):448-53 [16297090.001]
  • [Cites] Science. 2006 Jun 23;312(5781):1798-802 [16794079.001]
  • [Cites] Dig Dis Sci. 2006 Aug;51(8):1371-9 [16868827.001]
  • [Cites] Hum Pathol. 2006 Oct;37(10):1333-43 [16949920.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Nov;6(7):579-602 [17100565.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):387-98 [17011067.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):118-45 [17159189.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):64-77 [17113234.001]
  • [Cites] J Thorac Oncol. 2007 May;2(5):414-22 [17473657.001]
  • [Cites] World J Surg. 2007 Jul;31(7):1458-68 [17516110.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:53-77 [11264450.001]
  • (PMID = 19061514.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2613415
  •  go-up   go-down


34. Kimura M, Tsuda H, Morita D, Shinto E, Tanimoto T, Ichikura T, Mochizuki H, Matsubara O: Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma. Jpn J Clin Oncol; 2005 Jun;35(6):324-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma.
  • METHODS: Endoscopic biopsy specimens and specimens of whole representative cut surfaces of corresponding surgically resected tumors were obtained from 14 patients with gastric carcinoma, and immunohistochemistry and fluorescence in situ hybridization were then performed to determine the protein expression and gene amplification profiles, respectively, of EGFR and c-erbB-2 in these biopsy and surgical specimens.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / biosynthesis. Receptor, Epidermal Growth Factor / biosynthesis. Receptor, ErbB-2 / biosynthesis. Stomach / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Biopsy / methods. Gastrectomy. Gastroscopy. Gene Amplification. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15928192.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


35. Calcagno DQ, Leal MF, Seabra AD, Khayat AS, Chen ES, Demachki S, Assumpção PP, Faria MH, Rabenhorst SH, Ferreira MV, de Arruda Cardoso Smith M, Burbano RR: Interrelationship between chromosome 8 aneuploidy, C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma. World J Gastroenterol; 2006 Oct 14;12(38):6207-11
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interrelationship between chromosome 8 aneuploidy, C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma.
  • Immunostaining for C-MYC and dual-color fluorescence in situ hybridization (FISH) for C-MYC gene and chromosome 8 centromere were performed.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 8. Genes, myc. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aneuploidy. Brazil. Gene Amplification. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 1998 Nov;107(1):61-4 [9809036.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):1-11 [9858526.001]
  • [Cites] Exp Mol Pathol. 1999 Jun;66(2):140-8 [10409442.001]
  • [Cites] Exp Mol Pathol. 1999 Jun;66(2):157-62 [10409444.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Braz J Med Biol Res. 2004 Dec;37(12):1831-8 [15558189.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45 [16064138.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6B):4069-74 [16309200.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Aug;169(1):45-9 [16875936.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):2909-14 [16886612.001]
  • [Cites] J Korean Med Sci. 1999 Oct;14(5):526-30 [10576148.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Mar;117(2):97-103 [10704677.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3139-46 [10955795.001]
  • [Cites] Histopathology. 2000 Sep;37(3):241-9 [10971700.001]
  • [Cites] Histopathology. 2001 Feb;38(2):111-9 [11207824.001]
  • [Cites] World J Gastroenterol. 2001 Jun;7(3):403-6 [11819799.001]
  • [Cites] Arq Gastroenterol. 2001 Oct-Dec;38(4):240-6 [12068534.001]
  • [Cites] Cancer Genet Cytogenet. 2002 May;135(1):23-7 [12072199.001]
  • [Cites] J Cell Mol Med. 2002 Apr-Jun;6(2):151-9 [12169201.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 1;140(1):66-9 [12550762.001]
  • [Cites] Cytopathology. 2003 Feb;14(1):5-11 [12588304.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 2;95(7):E3 [12671026.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1311-20 [13679439.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):155-9 [15015591.001]
  • [Cites] World J Gastroenterol. 2004 Jun 15;10(12):1759-62 [15188501.001]
  • [Cites] Nature. 1983 Nov 10-16;306(5939):194-6 [6646201.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(13):4834-8 [3014513.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Aug;22(4):295-307 [3731046.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Jan;24(1):63-73 [3791173.001]
  • [Cites] Recent Results Cancer Res. 1994;136:179-202 [7863095.001]
  • [Cites] Int J Cancer. 1996 May 29;66(5):594-9 [8647618.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Dec;92(2):122-9 [8976368.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):226-32 [9010095.001]
  • [Cites] J Pathol. 1997 Apr;181(4):381-6 [9196434.001]
  • [Cites] Acta Chir Hung. 1997;36(1-4):119-21 [9408311.001]
  • [Cites] J Clin Pathol. 1997 Nov;50(11):896-903 [9462237.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Apr 1;102(1):88-90 [9530349.001]
  • [Cites] Lab Invest. 1998 Sep;78(9):1143-53 [9759658.001]
  • (PMID = 17036397.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4088119
  •  go-up   go-down


36. Jüttner S, Wissmann C, Jöns T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W, Höcker M: Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol; 2006 Jan 10;24(2):228-40
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.
  • MATERIALS AND METHODS: VEGF-C, VEGF-D, and VEGFR-3 were analyzed in 91 R(0)-resected primary gastric adenocarcinomas, corresponding noncancerous gastric mucosa, and lymph node metastases employing immunohistochemistry and/or in situ hybridization.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenocarcinoma / mortality. Stomach Neoplasms / chemistry. Stomach Neoplasms / mortality. Vascular Endothelial Growth Factor D / analysis. Vascular Endothelial Growth Factor Receptor-3 / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16344322.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


37. Zhao CH, Li QF: Altered profiles of nuclear matrix proteins during the differentiation of human gastric mucous adenocarcinoma MGc80-3 cells. World J Gastroenterol; 2005 Aug 14;11(30):4628-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered profiles of nuclear matrix proteins during the differentiation of human gastric mucous adenocarcinoma MGc80-3 cells.
  • AIM: To find and identify specific nuclear matrix proteins associated with proliferation and differentiation of carcinoma cells, which will be potential markers for cancer diagnosis and targets in cancer therapy.
  • Spots of nuclear matrix proteins differentially expressed were excised and subjected to in situ digestion with trypsin.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Neoplasm Proteins / metabolism. Nuclear Matrix-Associated Proteins / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094700.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Nuclear Matrix-Associated Proteins
  • [Other-IDs] NLM/ PMC4615401
  •  go-up   go-down


38. Szkaradkiewicz A, Majewski W, Wal M, Czyzak M, Majewski P, Bierła J, Kuch A: Epstein-Barr virus (EBV) infection and p53 protein expression in gastric carcinoma. Virus Res; 2006 Jun;118(1-2):115-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the presented studies p53 protein expression was evaluated in samples of gastric carcinoma originating from 32 selected adult patients (with documented diagnosis of adenocarcinoma of the stomach and without the presence of Helicobacter pylori infection).
  • EBV infection was detected testing the tissue material for the presence of EBER by RNA in situ hybridization (ISH) and testing sera of the patients for EBV-specific antibodies.
  • [MeSH-major] Adenocarcinoma / virology. Epstein-Barr Virus Infections / complications. Stomach Neoplasms / virology. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Aged. Antibodies, Viral / blood. Female. Herpesvirus 4, Human. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. RNA, Viral / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16413625.001).
  • [ISSN] 0168-1702
  • [Journal-full-title] Virus research
  • [ISO-abbreviation] Virus Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


39. Sonoda R, Naomoto Y, Shirakawa Y, Fujiwara Y, Yamatsuji T, Noma K, Tanabe S, Takaoka M, Gunduz M, Tsujigiwa H, Nagatsuka H, Ohara N, Yoshino T, Takubo K, Vieth M, Tanaka N: Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma. Histopathology; 2010 Jul;57(1):90-100
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Metaplastic changes secondary to chronic inflammation at the gastro-oesophageal junction and at the pyloric antrum are recognized as the premalignant conditions of Barrett's oesophageal adenocarcinoma and intestinal-type gastric carcinoma (GC), respectively.
  • METHODS AND RESULTS: First, expression of HPSE and COX-2 in 78 clinical tissues of Barrett's oesophagus was examined by immunohistochemistry and in situ hybridization.
  • These molecules may play an important role during the development of inflammation-related adenocarcinoma of the upper gastrointestinal tract.
  • [MeSH-major] Adenocarcinoma / enzymology. Barrett Esophagus / enzymology. Cyclooxygenase 2 / metabolism. Esophageal Neoplasms / enzymology. Glucuronidase / metabolism. Stomach Neoplasms / enzymology
  • [MeSH-minor] Base Sequence. Carcinoma in Situ / enzymology. Carcinoma in Situ / genetics. Carcinoma in Situ / pathology. Cell Line, Tumor. DNA Primers / genetics. Humans. Microvessels / pathology. Neovascularization, Pathologic. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Up-Regulation

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20653782.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


40. Maqani N, Belkhiri A, Moskaluk C, Knuutila S, Dar AA, El-Rifai W: Molecular dissection of 17q12 amplicon in upper gastrointestinal adenocarcinomas. Mol Cancer Res; 2006 Jul;4(7):449-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DNA amplification at 17q is frequently detected in upper gastrointestinal adenocarcinomas (UGC; stomach and esophagus).
  • In this study, we did fluorescence in situ hybridization on a tissue microarray that contained 304 UGCs and 89 normal stomach samples using a approximately 168-kb BAC clone (CTD-2019C10) that maps to 17q12-q21.1.
  • Adenocarcinomas of gastroesophageal junction and lower esophagus had the highest frequency of amplification (45%) compared with stomach tumors (27%; P = 0.04).
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 17 / genetics. Esophageal Neoplasms / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Female. Gene Amplification. Gene Dosage. Humans. In Situ Hybridization, Fluorescence / methods. Male. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods


41. Omori Y, Nakayama F, Li D, Kanemitsu K, Semba S, Ito A, Yokozaki H: Alternative lengthening of telomeres frequently occurs in mismatch repair system-deficient gastric carcinoma. Cancer Sci; 2009 Mar;100(3):413-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In formalin-fixed and paraffin-embedded sections of the high frequency of microsatellite instability (MSI-H) and non-MSI-H gastric carcinomas, there was no difference in telomere length monitored by telomere intensity ratio using telomere-fluorescent in situ hybridization.
  • Conversely, the number of the alternative lengthening of telomeres-associated promyelocytic leukemia bodies (APBs) detected by combined promyelocytic leukemia immunofluorescence and telomere-fluorescent in situ hybridization was statistically higher (57%) in the MSI-H gastric carcinomas compared to that in non-MSI-H gastric carcinomas (19%, P = 0.026).
  • These results suggest that alternative lengthening of telomeres-mediated telomere maintenance plays an important role for microsatellite instability-mediated stomach carcinogenesis, as well as the telomerase ribonucleoprotein complex, although the incidence of MSI-H is low.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Mismatch Repair. Microsatellite Instability. Stomach Neoplasms / genetics. Telomerase / metabolism. Telomere / metabolism
  • [MeSH-minor] Humans. Image Processing, Computer-Assisted. Immunohistochemistry. In Situ Hybridization, Fluorescence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19154407.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


42. Ushiku T, Shinozaki A, Uozaki H, Iwasaki Y, Tateishi Y, Funata N, Seto Y, Fukayama M: Gastric carcinoma with osteoclast-like giant cells. Lymphoepithelioma-like carcinoma with Epstein-Barr virus infection is the predominant type. Pathol Int; 2010 Aug;60(8):551-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LELC is a poorly differentiated adenocarcinoma with prominent lymphoid stroma.
  • The LELC type (n = 4) showed similar histology to LELC of the stomach, except that they were accompanied by OGC and granulomatous reaction.
  • Epstein-Barr virus (EBV) infection was demonstrated by EBV-encoded RNA (EBER) in situ hybridization (ISH) in all the neoplastic cells.
  • Both LELC and non-LELC types are included in the differential diagnosis of isolated granulomatous gastritis, and EBER-ISH was useful for the identification of LELC type.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Neuroendocrine / pathology. Epstein-Barr Virus Infections / pathology. Giant Cells / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Herpesvirus 4, Human / genetics. Humans. In Situ Hybridization. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20618732.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


43. Rüschoff J, Nagelmeier I, Baretton G, Dietel M, Höfler H, Schildhaus HU, Büttner R, Schlake W, Stoss O, Kreipe HH: [Her2 testing in gastric cancer. What is different in comparison to breast cancer?]. Pathologe; 2010 May;31(3):208-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on data from a large multicenter phase III trial (ToGA study) trastuzumab has very recently been approved by the EMEA for metastatic gastric cancer and adenocarcinoma of the gastro-esophageal junction.
  • Evaluation of Her2 in situ hybridization (ISH) is similar to breast cancer with ratio values of > or =2.0 indicating Her2 gene amplification.
  • [MeSH-major] Breast Neoplasms / genetics. Receptor, ErbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Algorithms. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Gene Amplification. Humans. In Situ Hybridization. In Situ Hybridization, Fluorescence. Neoplasm Metastasis


44. Targa AC, César AC, Cury PM, Silva AE: Apoptosis in different gastric lesions and gastric cancer: relationship with Helicobacter pylori, overexpression of p53 and aneuploidy. Genet Mol Res; 2007;6(3):554-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its deregulation is associated with the occurrence of lesions such as in atrophic gastritis, peptic ulcers, intestinal metaplasia, and stomach tumorigenesis.
  • Thus, the aim of the present study was to investigate the frequency of apoptotic cells (apoptotic index, AI) by using two different immunohistochemical techniques, TUNEL and anti-activated caspase-3 antibody (CPP32), in gastric dyspepsia [chronic gastritis (CG, N = 34), chronic atrophic gastritis (CAG, N = 11), gastric ulcer (GU, N = 17), and intestinal metaplasia (IM, N = 15)], normal gastric mucosae (NM, N = 8), and gastric adenocarcinoma (GC, N = 12).
  • The relationship was investigated between the AI and Helicobacter pylori infection, diagnosed by PCR, overexpression of p53 protein determined by immunohistochemistry, and aneuploidy by fluorescence in situ hybridization, as performed by our laboratory in previous studies.
  • [MeSH-major] Apoptosis. Gene Expression Regulation, Neoplastic. Helicobacter pylori / metabolism. Stomach / microbiology. Stomach / pathology. Stomach Neoplasms / microbiology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aneuploidy. Caspase 3 / metabolism. Female. Humans. In Situ Hybridization. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17985308.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] EC 3.4.22.- / Caspase 3
  •  go-up   go-down


45. Dede M, Gezginç K, Ulubay M, Alanbay I, Güran S, Yenen M: A breast cancer patient with pelvic and gastric malignancy after adjuvant tamoxifen treatment for breast cancer. Eur J Gynaecol Oncol; 2008;29(2):200
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastric tumor, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Aged. Carcinoma in Situ / chemically induced. Endometrial Neoplasms / chemically induced. Female. Humans. Middle Aged. Stomach Neoplasms / chemically induced. Uterine Cervical Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459568.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


46. Ojima H, Saito K, Yamauchi H, Yamaki E, Idetu A, Hosouchi Y, Nishida Y, Tukada K, Kato H, Kuwano H: P16 protein abnormality in Epstein-Barr virus-associated gastric carcinomas. Anticancer Res; 2006 Mar-Apr;26(2A):933-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten percent of gastric carcinomas, including lymphepithelioma-like carcinoma and adenocarcinoma, are associated with EBV infection.
  • MATERIALS AND METHODS: To clarify the relationship between p16 overexpression and EBV-associated gastric carcinomas, immunohistochemical analysis of p16 and detection of EBV by in situ hybridization were performed on 238 formalin-fixed and paraffin-embedded samples of gastric carcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / virology. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / metabolism. Stomach Neoplasms / metabolism. Stomach Neoplasms / virology
  • [MeSH-minor] Female. Genes, p16 / physiology. Herpesvirus 4, Human / genetics. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619489.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


47. Ma X, Chen K, Huang S, Zhang X, Adegboyega PA, Evers BM, Zhang H, Xie J: Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis; 2005 Oct;26(10):1698-705
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies indicate that the hedgehog pathway activation occurs in the stomach and other gastrointestinal cancers.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology. Trans-Activators / genetics
  • [MeSH-minor] Female. Gene Expression Regulation, Neoplastic. Hedgehog Proteins. Humans. In Situ Hybridization. Male. Neoplasm Staging. Oncogene Proteins / genetics. Receptors, Cell Surface / genetics. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15905200.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA94160
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gli protein; 0 / Hedgehog Proteins; 0 / Oncogene Proteins; 0 / Receptors, Cell Surface; 0 / SHH protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / patched receptors
  •  go-up   go-down


48. van Duin M, van Marion R, Vissers KJ, Hop WC, Dinjens WN, Tilanus HW, Siersema PD, van Dekken H: High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of putative progression markers for gastroesophageal junction adenocarcinomas. Cytogenet Genome Res; 2007;118(2-4):130-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Quantitative RT-PCR analysis of these seven genes was subsequently performed on a panel of 24 gastroesophageal samples, including 13 cell lines, two xenografts and nine normal stomach controls.
  • Significant overexpression was found for MYC and EXT1 in GEJ adenocarcinoma cell lines and xenografts compared to normal controls.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 8. Esophageal Neoplasms / genetics. Esophagogastric Junction / pathology. Nucleic Acid Conformation. Stomach Neoplasms / genetics
  • [MeSH-minor] Disease Progression. Humans. In Situ Hybridization, Fluorescence. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 18000363.001).
  • [ISSN] 1424-859X
  • [Journal-full-title] Cytogenetic and genome research
  • [ISO-abbreviation] Cytogenet. Genome Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


49. Bizari L, Borim AA, Leite KR, Gonçalves Fde T, Cury PM, Tajara EH, Silva AE: Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. Cancer Genet Cytogenet; 2006 Feb;165(1):41-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CCND1 gene amplification (45%) was more prevalent than polysomy (25%) in esophageal carcinoma, but the pattern observed was similar in gastric adenocarcinoma (10% amplification, 15% polysomy).
  • The kappa-statistics revealed a fair agreement in both types of tumors only in overexpression and amplification of the CCND1 gene; the ERBB2 gene showed a fair agreement in amplification and polysomy and the level of protein expression in gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Cyclin D1 / genetics. Esophageal Neoplasms / genetics. Gene Amplification. Genes, erbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. Female. Gene Expression Regulation, Neoplastic. Helicobacter Infections / epidemiology. Helicobacter pylori. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Receptor, ErbB-2 / genetics. Survival Analysis


50. Vieth M, Stolte M: Pathology of early upper GI cancers. Best Pract Res Clin Gastroenterol; 2005 Dec;19(6):857-69
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucosal oesophageal carcinoma (squamous cell carcinoma and adenocarcinoma) can be subdivided into m1-m3 and m1-m4.
  • Distinction of high-grade intraepithelial neoplasia and mucosal carcinoma is without clinical relevance since the diagnosis of high-grade intraepithelial neoplasia should always first lead to a (diagnostic) endoscopic resection.
  • The final histological diagnosis could then be made on the resection specimen.
  • Diagnosis of low-grade intraepithelial neoplasia is often confused with regenerative changes.
  • [MeSH-major] Esophageal Neoplasms / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Carcinoma / pathology. Carcinoma in Situ / diagnosis. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Early Diagnosis. Humans. Neoplasm Invasiveness / diagnosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16338646.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 30
  •  go-up   go-down


51. Sato T, Muto I, Fushiki M, Hasegawa M, Hasegawa M, Sakai T, Sekiya M: Metastatic breast cancer from gastric and ovarian cancer, mimicking inflammatory breast cancer: report of two cases. Breast Cancer; 2008;15(4):315-20
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast biopsy revealed poorly differentiated adenocarcinoma with signet-ring cells or clear cell carcinoma in the lymphatic vessels and the parenchyma without an in situ lesion, similar to primary lesions of the stomach or ovary, respectively.
  • Immunohistochemical staining for estrogen receptor, progesterone receptor, and gross cystic disease fluid protein 15 was of value for correct diagnosis.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Ovarian Neoplasms / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / therapy. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed


52. Kim B, Byun SJ, Kim YA, Kim JE, Lee BL, Kim WH, Chang MS: Cell cycle regulators, APC/beta-catenin, NF-kappaB and Epstein-Barr virus in gastric carcinomas. Pathology; 2010 Jan;42(1):58-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We investigated cell cycle regulators (p53, p21, Rb), APC, beta-catenin and NF-kappaB using immunohistochemistry and EBV using in situ hybridisation for EBV encoded small RNAs in 117 cases of gastric carcinoma.
  • EBV positive gastric carcinomas were located in the upper third of the stomach, and more were of the diffuse or mixed types than the EBV negative group (p < 0.05).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Epstein-Barr Virus Infections / metabolism. Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / isolation & purification. Stomach Neoplasms / metabolism. Stomach Neoplasms / virology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / virology. Adenomatous Polyposis Coli Protein / metabolism. Adult. Aged. Aged, 80 and over. Cell Cycle Proteins / metabolism. Comorbidity. Female. Humans. In Situ Hybridization. Kaplan-Meier Estimate. Korea / epidemiology. Male. Middle Aged. NF-kappa B / metabolism. Neoplasm Staging. Survival Rate. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20025482.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / NF-kappa B; 0 / beta Catenin
  •  go-up   go-down


53. Wang YZ, Cao YQ, Wu JN, Chen M, Cha XY: Expression of nitric oxide synthase in human gastric carcinoma and its relation to p53, PCNA. World J Gastroenterol; 2005 Jan 7;11(1):46-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We then examined the expression of NOS, p53, PCNA in 85 samples of human gastric cancer was examined by immunohistochemistry, and NOS mRNA expression in 85 gastric cancer tissue specimens by in situ hybridization.
  • In situ hybridization analysis showed that iNOS mRNA expression was significantly stronger than eNOS mRNA expression in gastric cancer tissue (chi(2) = 10.23, P<0.01).
  • The expression of neuronal nitric oxide synthase (nNOS) was not examined by immunohistochemistry and in situ hybridization in gastric cancer specimens and normal gastric mucosa.
  • [MeSH-major] Adenocarcinoma / physiopathology. Nitric Oxide Synthase / genetics. Proliferating Cell Nuclear Antigen / metabolism. Stomach Neoplasms / physiopathology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization. Lymphatic Metastasis. Male. Middle Aged. Nitric Oxide Synthase Type II

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609395.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  • [Other-IDs] NLM/ PMC4205382
  •  go-up   go-down


54. Furuya T, Uchiyama T, Adachi A, Chochi Y, Oga A, Kawauchi S, Ishiglo K, Sasaki K: Relation of DNA ploidy to genetic aberrations detected by chromosomal CGH and FISH in gastric adenocarcinomas. Oncol Rep; 2006 Jun;15(6):1491-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, numerical aberrations in chromosomes 7, 11, 17, and 18 were evaluated by fluorescence in situ hybridization (FISH).
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Ploidies. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Neoplasm / genetics. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Nucleic Acid Hybridization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685384.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


55. Mitsui F, Dobashi Y, Imoto I, Inazawa J, Kono K, Fujii H, Ooi A: Non-incidental coamplification of Myc and ERBB2, and Myc and EGFR, in gastric adenocarcinomas. Mod Pathol; 2007 Jun;20(6):622-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A fluorescence in situ hybridization (FISH) analysis revealed that nine (19%) of the 47 tumors with protein overexpression had cancer cells with high levels of Myc amplification, whereas only seven (6%) of the 122 tumors without protein overexpression showed high-level Myc gene amplification.
  • [MeSH-major] Adenocarcinoma / metabolism. Proto-Oncogene Proteins c-myc / biosynthesis. Receptor, Epidermal Growth Factor / biosynthesis. Receptor, ErbB-2 / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Cell Nucleus / metabolism. Gene Dosage. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lymph Nodes / metabolism. Lymphatic Metastasis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431415.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myc; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


56. Liu YJ, Yan PS, Li J, Jia JF: Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer. World J Gastroenterol; 2005 Nov 14;11(42):6601-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To investigate the relationship between the expression levels of nm23 mRNA, CD44s, and CD44v6, and oncogenesis, development and metastasis of human gastric adenocarcinoma, colorectal adenocarcinoma, intraductal carcinoma of breast, and lung cancer.
  • METHODS: Using tissue microarray by immuhistochemical (IHC) staining and in situ hybridization (ISH), we examined the expression levels of nm23 mRNA, CD44s, and CD44v6 in 62 specimens of human gastric adenocarcinoma and 62 specimens of colorectal adenocarcinoma; the expression of CD44s and CD44v6 in 120 specimens of intraductal carcinoma of breast and 20 specimens of normal breast tissue; the expression of nm23 mRNA in 72 specimens of human lung cancer and 23 specimens of normal tissue adjacent to cancer.
  • RESULTS: The expression of nm23 mRNA in the tissues of gastric and colorectal adenocarcinoma was not significantly different from that in the normal tissues adjacent to cancer (P>0.05), and was not associated with the invasion of tumor and the pathology grade of adenocarcinoma (P>0.05).
  • However, the expression of nm23 mRNA was correlated negatively to the lymph node metastasis of gastric and colorectal adenocarcinoma (r = -0.49, P<0.01; r = -4.93, P<0.01).
  • The expression of CD44s in the tissues of gastric and colorectal adenocarcinoma was significantly different from that in the normal tissues adjacent to cancer (P<0.05; P<0.01).
  • CD44v6 was expressed in the tissues of gastric and colorectal adenocarcinoma only, the expression of CD44v6 was significantly associated with the lymph node metastasis, invasion and pathological grade of the tumor (r = 0.47, P<0.01; r = 5.04, P<0.01).
  • [MeSH-minor] Antigens, Neoplasm / genetics. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Female. Humans. Immunohistochemistry. In Situ Hybridization. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. NM23 Nucleoside Diphosphate Kinases. Neoplasm Metastasis. Nucleoside-Diphosphate Kinase. Protein Array Analysis. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425351.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Glycoproteins; 0 / NM23 Nucleoside Diphosphate Kinases; 0 / RNA, Messenger; EC 2.7.4.6 / NME1 protein, human; EC 2.7.4.6 / Nucleoside-Diphosphate Kinase
  • [Other-IDs] NLM/ PMC4355751
  •  go-up   go-down


57. Fukayama M: Epstein-Barr virus and gastric carcinoma. Pathol Int; 2010 May;60(5):337-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sequential events in the gastric mucosa could be traced from EBV infection of the pit cells to fully developed carcinomas by EBV encoded small RNA (EBER)-in situ hybridization.
  • DNA methylation in EBV-infected stomach cells may be due to overdrive of the cellular defense against foreign DNA, which eventually leads to the development of EBV-associated GC.
  • [MeSH-major] Adenocarcinoma / virology. Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / pathogenicity. Stomach Neoplasms / virology
  • [MeSH-minor] Cell Line, Tumor. CpG Islands / genetics. Gene Expression Regulation. Gene Silencing. Host-Pathogen Interactions. Humans. In Situ Hybridization. Methylation. PTEN Phosphohydrolase / genetics. PTEN Phosphohydrolase / metabolism. RNA, Neoplasm / analysis. RNA, Viral / analysis. Viral Matrix Proteins / genetics. Viral Matrix Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518883.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / RNA, Neoplasm; 0 / RNA, Viral; 0 / Viral Matrix Proteins; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 84
  •  go-up   go-down


58. Ma XL, Sun HJ, Wang YS, Huang SH, Xie JW, Zhang HW: Study of Sonic hedgehog signaling pathway related molecules in gastric carcinoma. World J Gastroenterol; 2006 Jul 7;12(25):3965-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Expression of Shh in 56 gastric specimens including non-cancerous gastric tissues, gastric adenocarcinoma, gastric squamous cell carcinoma was detected by RT-PCR, in situ hybridization and immunohistochemistry.
  • Expression of Gli1 was observed by in situ hybridization.
  • RESULTS: The positive rate of Shh and Gli1 expression was 0.0%, 0.0% in non-cancerous gastric tissues while it was 66.7%, 57.8% respectively in gastric adenocarcinoma, and 100%, 100% respectively in gastric squamous cell carcinoma.
  • Elevated expression of Shh and Gli1 in gastric tubular adenocarcinoma was associated with poorly differentiated tumors while the expression was absent in gastric mucinous adenocarcinoma.
  • CONCLUSION: The elevated expression of Shh and Gli1 in gastric adenocarcinoma and gastric squamous cell carcinoma shows the involvement of activated Shh signaling in the cellular proliferation of gastric carcinogenesis.
  • It suggests Shh signaling gene may be a new and good target gene for gastric tumor diagnosis and therapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Stomach Neoplasms / metabolism. Trans-Activators / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Hedgehog Proteins. Humans. RNA, Messenger / metabolism. Signal Transduction. Stomach / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 2000 Jun;127(12):2763-72 [10821773.001]
  • [Cites] Cancer Lett. 2005 Sep 28;227(2):99-104 [16112412.001]
  • [Cites] Nat Immunol. 2001 Feb;2(2):172-80 [11175816.001]
  • [Cites] Genes Dev. 2001 Dec 1;15(23):3059-87 [11731473.001]
  • [Cites] Nat Neurosci. 2002 Feb;5(2):103-10 [11788837.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):892-7 [12192414.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Gut. 2002 Nov;51(5):628-33 [12377798.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Lab Invest. 2003 Dec;83(12):1829-37 [14691301.001]
  • [Cites] Nature. 1996 Oct 3;383(6599):407-13 [8837770.001]
  • [Cites] Nat Genet. 1998 Sep;20(1):58-61 [9731532.001]
  • [Cites] Neuron. 1999 Jan;22(1):103-14 [10027293.001]
  • [Cites] J Mol Med (Berl). 1999 Jun;77(6):459-68 [10475061.001]
  • [Cites] Mol Cell Biol. 2000 Dec;20(23):9055-67 [11074003.001]
  • (PMID = 16810741.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / RNA, Messenger; 0 / SHH protein, human; 0 / Trans-Activators; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC4087703
  •  go-up   go-down


59. Zhang W, Chu YQ, Ye ZY, Zhao ZS, Tao HQ: Expression of hepatocyte growth factor and basic fibroblast growth factor as prognostic indicators in gastric cancer. Anat Rec (Hoboken); 2009 Aug;292(8):1114-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In situ hybridization was used to detect the expression of HGF and bFGF mRNAs, and immunohistochemistry was used to detect CD34 in 105 gastric cancer tissues and in 20 normal control tissues.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Fibroblast Growth Factor 2 / biosynthesis. Hepatocyte Growth Factor / biosynthesis. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Aged. Antigens, CD34 / metabolism. Endothelial Cells / metabolism. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Neovascularization, Pathologic. Prognosis. RNA, Messenger / analysis. RNA, Messenger / biosynthesis. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19533745.001).
  • [ISSN] 1932-8494
  • [Journal-full-title] Anatomical record (Hoboken, N.J. : 2007)
  • [ISO-abbreviation] Anat Rec (Hoboken)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 103107-01-3 / Fibroblast Growth Factor 2; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


60. van Beek J, zur Hausen A, Snel SN, Berkhof J, Kranenbarg EK, van de Velde CJ, van den Brule AJ, Middeldorp JM, Meijer CJ, Bloemena E: Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases. Am J Surg Pathol; 2006 Jan;30(1):59-65
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The PT (n = 28) and its LNs were analyzed by EBER RNA in situ hybridization and by immunohistochemistry for MHC class I and II expression, for CD3, CD8, CD4, CD20, CD56, CD83, and Granzyme B (GzB) expression.
  • [MeSH-major] Adenocarcinoma / pathology. Epstein-Barr Virus Infections / virology. Lymphatic Metastasis / immunology. Stomach Neoplasms / pathology. T-Lymphocytes, Cytotoxic / immunology. Tumor Virus Infections / immunology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Herpesvirus 4, Human / immunology. Herpesvirus 4, Human / isolation & purification. Humans. Immunohistochemistry. In Situ Hybridization. Lymphocyte Subsets / immunology. Lymphocytes, Tumor-Infiltrating / immunology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330943.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


61. De Caro G, Pagano N, Malesci A, Hervoso C, Danese S, Romeo F, Delconte G, Repici A: Endoclipping for gastric perforation secondary to second session of EMRC in locally residual early gastric cancer: a case report. Dig Liver Dis; 2009 Jul;41(7):e32-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 72-year-old woman underwent gastric endoscopic mucosal resection with a cap-fitted endoscope for an adenocarcinoma in situ.
  • [MeSH-major] Adenocarcinoma / surgery. Gastroscopy / adverse effects. Neoplasm Recurrence, Local / surgery. Stomach Diseases / etiology. Stomach Neoplasms / surgery. Surgical Instruments
  • [MeSH-minor] Aged. Cicatrix / pathology. Cicatrix / surgery. Female. Humans. Iatrogenic Disease. Stomach / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18620913.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


62. Lima MA, Ferreira MV, Barros MA, Pardini MI, Ferrasi AC, Mota RM, Rabenhorst SH: Relationship between EBV infection and expression of cellular proteins c-Myc, Bcl-2, and Bax in gastric carcinomas. Diagn Mol Pathol; 2008 Jun;17(2):82-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: One hundred patients of gastric carcinoma, obtained from 2 hospitals in Fortaleza, Brazil were assessed for the presence of EBV by in situ hybridization, for the expression of Bcl-2, Bax, and c-Myc (nuclear and cytoplasmic staining) proteins by immunohistochemistry techniques, and for the apoptotic index.
  • [MeSH-major] Adenocarcinoma / metabolism. Epstein-Barr Virus Infections / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-myc / metabolism. Stomach Neoplasms / metabolism. bcl-2-Associated X Protein / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Biomarkers, Tumor / metabolism. Female. Gastrectomy. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Humans. In Situ Hybridization. Male. Middle Aged. RNA, Viral / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382371.001).
  • [ISSN] 1533-4066
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / Biomarkers, Tumor; 0 / Epstein-Barr virus encoded RNA 1; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Viral; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


63. Liu GY, Liu KH, Zhang Y, Wang YZ, Wu XH, Lu YZ, Pan C, Yin P, Liao HF, Su JQ, Ge Q, Luo Q, Xiong B: Alterations of tumor-related genes do not exactly match the histopathological grade in gastric adenocarcinomas. World J Gastroenterol; 2010 Mar 7;16(9):1129-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To investigate the diverse characteristics of different pathological gradings of gastric adenocarcinoma (GA) using tumor-related genes.
  • Expressions of 15 major tumor-related genes were detected by RNA in situ hybridization along with 3' terminal digoxin-labeled anti-sense single stranded oligonucleotide and locked nucleic acid modifying probe within the tissue array.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Biomarkers, Tumor / genetics. Cell Differentiation / genetics. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. RNA, Messenger / analysis. ROC Curve. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):262-7 [10618406.001]
  • [Cites] Ann N Y Acad Sci. 2009 Oct;1177:198-204 [19845622.001]
  • [Cites] Ai Zheng. 2003 Nov;22(11):1204-8 [14613654.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Expert Rev Mol Med. 2002 Mar;4(6):1-12 [14987390.001]
  • [Cites] Hepatogastroenterology. 2004 Jan-Feb;51(55):273-6 [15011884.001]
  • [Cites] Nat Rev Immunol. 2004 May;4(5):348-59 [15122200.001]
  • [Cites] Pathobiology. 2004;71(4):201-10 [15263809.001]
  • [Cites] Nature. 1991 Jun 6;351(6326):453-6 [2046748.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] Nature. 1992 Jul 2;358(6381):15-6 [1614522.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):786-7 [8479514.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4855-78 [8069852.001]
  • [Cites] J Surg Oncol. 1996 Sep;63(1):36-40 [8841464.001]
  • [Cites] Surg Today. 1998;28(10):1015-21 [9786572.001]
  • [Cites] Hum Mutat. 2006 Mar;27(3):215-9 [16419085.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1711-42 [16958083.001]
  • [Cites] Autophagy. 2007 Jan-Feb;3(1):28-31 [16969128.001]
  • [Cites] Autophagy. 2007 Jan-Feb;3(1):69-71 [17106237.001]
  • [Cites] Cell Cycle. 2007 May 2;6(9):1006-10 [17457049.001]
  • [Cites] Int J Exp Pathol. 2007 Jun;88(3):175-83 [17504447.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2119-52 [17939129.001]
  • [Cites] Histopathology. 2008 Mar;52(4):494-9 [18315602.001]
  • [Cites] Cell Cycle. 2008 Aug;7(15):2299-305 [18677114.001]
  • [Cites] APMIS. 2008 Jul-Aug;116(7-8):586-601 [18834404.001]
  • [Cites] Future Oncol. 2008 Dec;4(6):815-24 [19086848.001]
  • [Cites] Nat Rev Cancer. 2008 Sep;8(9):671-82 [18650841.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):440-8 [19147556.001]
  • [Cites] Oncol Rep. 2009 Feb;21(2):387-93 [19148512.001]
  • [Cites] Bioinformatics. 2009 Feb 1;25(3):331-7 [19088122.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3625-33 [19336573.001]
  • [Cites] Nature. 2009 Apr 30;458(7242):1127-30 [19407794.001]
  • [Cites] Rom J Morphol Embryol. 2009;50(2):185-94 [19434309.001]
  • [Cites] Pathol Int. 2009 Jun;59(6):359-67 [19490465.001]
  • [Cites] Mutat Res. 2009 Jul 31;668(1-2):117-32 [19101574.001]
  • [Cites] Cell Cycle. 2009 Aug 15;8(16):2549-56 [19597346.001]
  • [Cites] Cell Cycle. 2009 Aug 15;8(16):2518-22 [19625770.001]
  • [Cites] Cell Cycle. 2009 Aug 15;8(16):2481 [19657223.001]
  • [Cites] Korean J Gastroenterol. 2009 Aug;54(2):83-98 [19696536.001]
  • [Cites] Biochim Biophys Acta. 2009 Sep;1793(9):1524-32 [19371598.001]
  • [Cites] Nat Rev Cancer. 2009 Oct;9(10):714-23 [19730431.001]
  • [Cites] Comput Biol Med. 2009 Nov;39(11):953-60 [19716554.001]
  • [Cites] Ann Clin Lab Sci. 2000 Jul;30(3):239-47 [10945563.001]
  • (PMID = 20205286.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2835792
  •  go-up   go-down


64. Shinozaki A, Ushiku T, Fukayama M: Prominent Mott cell proliferation in Epstein-Barr virus-associated gastric carcinoma. Hum Pathol; 2010 Jan;41(1):134-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In situ hybridization for Epstein-Barr virus (EBV)-encoded small RNA (EBER) labeled the carcinoma cells but not the lymphoplasmacytic cells.
  • The differential diagnosis included primary gastric lymphoma and nonneoplastic conditions such as Russell body gastritis; EBER in situ hybridization was helpful in their differentiation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human / isolation & purification. Plasma Cells / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Gastrectomy. Gastritis / diagnosis. Humans. In Situ Hybridization. Inclusion Bodies / pathology. Lymphoma / diagnosis. Male. Neoplasm Staging. RNA, Viral / analysis. RNA-Binding Proteins / metabolism. Ribosomal Proteins / metabolism. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19665167.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Viral; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


65. Ribeiro-Mourão F, Pimentel-Nunes P, Dinis-Ribeiro M: Endoscopic submucosal dissection for gastric lesions: results of an European inquiry. Endoscopy; 2010 Oct;42(10):814-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most cases were non-invasive high-grade intraepithelial neoplasia (44 %) or adenocarcinoma (36 %).
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Dissection / utilization. Gastric Mucosa / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 20886399.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


66. Okines AF, Cunningham D: Trastuzumab in gastric cancer. Eur J Cancer; 2010 Jul;46(11):1949-59
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HER-2 over-expression, defined as HER-2 protein over-expression using immunohistochemistry scored as 3+ and/or erbB-2 amplification detected by fluorescent in situ hybridisation, was detected in 22.1% of 3807 patients with advanced gastric and oesophagogastric junction (OGJ) adenocarcinoma screened for eligibility for the phase III ToGA study.
  • The international multicentre randomised phase III ToGA study assessed the addition of trastuzumab to a cisplatin plus fluoropyrimidine (FP) chemotherapy doublet for patients with HER-2-positive advanced gastric or OGJ adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20542421.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Quinazolines; 0VUA21238F / lapatinib; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


67. Geddert H, Zur Hausen A, Gabbert HE, Sarbia M: EBV-infection in cardiac and non-cardiac gastric adenocarcinomas is associated with promoter methylation of p16, p14 and APC, but not hMLH1. Anal Cell Pathol (Amst); 2010;33(3):143-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred GC were tested by RNA-in situ hybridization for the presence of EBV by EBV-encoded small RNA (EBER).
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Adenomatous Polyposis Coli Protein / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Methylation / genetics. Nuclear Proteins / genetics. Promoter Regions, Genetic / genetics. Stomach Neoplasms / genetics. Tumor Suppressor Protein p14ARF / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / virology. Adult. Aged. Aged, 80 and over. Epstein-Barr Virus Infections / genetics. Epstein-Barr Virus Infections / physiopathology. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20978327.001).
  • [ISSN] 2210-7185
  • [Journal-full-title] Analytical cellular pathology (Amsterdam)
  • [ISO-abbreviation] Anal Cell Pathol (Amst)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / APC protein, human; 0 / Adaptor Proteins, Signal Transducing; 0 / Adenomatous Polyposis Coli Protein; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p14ARF
  • [Other-IDs] NLM/ PMC4605817
  •  go-up   go-down


68. von Rahden BH, Langner C, Brücher BL, Stein HJ, Sarbia M: No association of primary adenocarcinomas of the small bowel with Epstein-Barr virus infection. Mol Carcinog; 2006 May;45(5):349-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have investigated the prevalence of EBER expression (EBV-encoded small RNAs) in a series of small bowel adenocarcinomas (n=56) utilizing RNA in situ hybridization (EBER-RISH).
  • [MeSH-major] Adenocarcinoma / virology. Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / genetics. Intestinal Neoplasms / virology. Intestine, Small / virology. Stomach Neoplasms / virology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. In Situ Hybridization. Male. Middle Aged. RNA, Viral / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16493667.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


69. Wu CS, Chen MF, Lee IL, Tung SY: Predictive role of nuclear factor-kappaB activity in gastric cancer: a promising adjuvant approach with caffeic acid phenethyl ester. J Clin Gastroenterol; 2007 Nov-Dec;41(10):894-900
Hazardous Substances Data Bank. 2-PHENYLETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We also performed electrophoretic mobility gel shift assay, real-time reverse transcription polymerase chain reaction, and enzyme-linked immunosorbent assay to evaluate the responses of AGS (a gastric adenocarcinoma epithelial cell line) human gastric cancer cells subsequent to H. pylori infection or CAPE treatment.
  • [MeSH-major] Adenocarcinoma / pathology. Caffeic Acids / pharmacology. Epithelial Cells / drug effects. Epithelial Cells / microbiology. Helicobacter pylori / pathogenicity. NF-kappa B / metabolism. Phenylethyl Alcohol / analogs & derivatives. Stomach Neoplasms / pathology
  • [MeSH-minor] Carcinoma in Situ / metabolism. Carcinoma in Situ / microbiology. Carcinoma in Situ / pathology. Cell Line, Tumor. Cell Nucleus / drug effects. Cell Nucleus / metabolism. Cell Nucleus / microbiology. Cell Survival. Helicobacter Infections / microbiology. Humans

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Gastroenterol. 2007 Nov-Dec;41(10):871-3 [18090154.001]
  • (PMID = 18090157.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caffeic Acids; 0 / NF-kappa B; G960R9S5SK / caffeic acid phenethyl ester; ML9LGA7468 / Phenylethyl Alcohol
  •  go-up   go-down


70. Vang R, Gown AM, Farinola M, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Judson K, Ronnett BM: p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol; 2007 May;31(5):653-63
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemical expression of p16 was assessed in 195 tumors, including 98 primary ovarian tumors (51 mucinous, 47 endometrioid, and 4 mixed mucinous-endometrioid tumors), 93 metastatic adenocarcinomas of known primary sites (colorectum: 34, endocervix: 19, pancreaticobiliary tract: 17, appendix: 7, stomach: 5), 11 metastatic adenocarcinomas of unknown origin (7 established as noncervical), and 4 adenocarcinomas of uncertain (primary ovarian vs. metastatic) origin.
  • The HPV status of the endocervical adenocarcinomas was determined by in situ hybridization and polymerase chain reaction (when in situ hybridization was negative).
  • Diffuse (>75% positive tumor cells) moderate to strong p16 expression is a sensitive (100%) and specific (97%) marker for identifying HPV-related endocervical adenocarcinomas metastatic to the ovary among the primary ovarian tumors and metastatic adenocarcinomas from other sites that are in the differential diagnosis of ovarian tumors having mucinous and/or endometrioid/endometrioidlike differentiation. p16 is useful as part of a panel of immunohistochemical markers for distinguishing primary ovarian tumors from metastases and, when diffusely positive, can suggest the cervix as a potential primary site for metastatic adenocarcinomas of unknown origin.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Carcinoma, Endometrioid / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Ovarian Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. DNA, Viral / analysis. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Papillomaviridae / genetics. Papillomavirus Infections. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460447.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral
  •  go-up   go-down


71. Bilal A, Baseer A, Ahmad M, Imran M, Abid M, Kalimullah M: Early results of oesophagectomy for carcinoma oesophagus in 1008 cases. J Ayub Med Coll Abbottabad; 2010 Oct-Dec;22(4):109-14
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 611 lower 1/3 tumours stomach involvement was present in 271 (44.35%) cases.
  • Adenocarcinoma was present in 516 (51.19%) cases, squamous cell carcinoma was present in 485 (48.11%), adenosquamous was 6 (0.59%) and carcinoma in situ was present in 1 case (0.09%).
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22455275.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


72. Zheng HC, Xu XY, Yu M, Takahashi H, Masuda S, Takano Y: The role of Reg IV gene and its encoding product in gastric carcinogenesis. Hum Pathol; 2010 Jan;41(1):59-69
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To clarify the role of Reg IV in gastric carcinogenesis and subsequent progression, we examined its expression by immunohistochemistry and in situ hybridization on tissue microarray containing gastric carcinoma, adjacent nonneoplastic mucosa, adenoma, intestinal metaplasia, or gastritis.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Regulation, Neoplastic. Lectins, C-Type / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Aged. Biomarkers, Tumor / metabolism. Blotting, Western. Carcinoma, Signet Ring Cell / genetics. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / secondary. Cell Line, Tumor. Cell Transformation, Neoplastic. DNA, Neoplasm / analysis. Female. Gastric Mucosa / metabolism. Gastritis / genetics. Gastritis / metabolism. Gastritis / pathology. Humans. In Situ Hybridization. Male. Middle Aged. Neoplasm Staging. Precancerous Conditions. Sequence Analysis, DNA. Tissue Array Analysis


73. Rojo F, Tabernero J, Albanell J, Van Cutsem E, Ohtsu A, Doi T, Koizumi W, Shirao K, Takiuchi H, Ramon y Cajal S, Baselga J: Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol; 2006 Sep 10;24(26):4309-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to assess the in situ biologic activity of the EGFR tyrosine kinase inhibitor gefitinib in gastric tumor samples in a phase II study.
  • METHODS: Patients with previously treated stage IV adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to receive gefitinib (250 or 500 mg/d).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma / drug therapy. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / metabolism. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 Dec 10;24(35):5620. Ramon Cajal, S [corrected to Ramon y Cajal, S]
  • (PMID = 16963731.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; S65743JHBS / gefitinib
  •  go-up   go-down


74. Yoshiwara E, Koriyama C, Akiba S, Itoh T, Minakami Y, Chirinos JL, Watanabe J, Takano J, Miyagui J, Hidalgo H, Chacon P, Linares V, Eizuru Y: Epstein-Barr virus-associated gastric carcinoma in Lima, Peru. J Exp Clin Cancer Res; 2005 Mar;24(1):49-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein-Barr virus (EBV)-associated gastric carcinoma (EBVaGC) was identified by the in situ hybridization (ISH) technique to detect EBV-encoded small RNA (EBER) in gastric tissue.
  • Other clinicopathological features of EBVaGC in Peru were similar to those found in literature: EBVaGC showed no age dependence, a predominance in the non-antrum part of the stomach, and high frequencies in histological subtypes of moderately differentiated tubular adenocarcinoma and solid poorly differentiated adenocarcinoma.
  • There was a case of well-differentiated adenocarcinoma showing a partial EBER-1-positive staining.
  • In this carcinoma, the tumor in the body (middle third of the stomach) was EBER-1 positive but the tumor in the stomach antrum showed no noticeable EBER-1 ISH staining.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / physiology. Stomach Neoplasms / complications. Stomach Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943031.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


75. Ashurst HL, Varro A, Dimaline R: Regulation of mammalian gastrin/CCK receptor (CCK2R) expression in vitro and in vivo. Exp Physiol; 2008 Feb;93(2):223-36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The gastrin/CCK receptor (CCK2R) mediates the physiological functions of gastrin in the stomach, including stimulation of acid secretion and cellular proliferation and migration, but little is known about the factors that regulate its expression.
  • We identified endogenous CCK2R expression in several cell lines and used luciferase promoter-reporter constructs to define the minimal promoter required for transcription in human gastric adenocarcinoma, AGS, and rat gastric mucosa, RGM1, cells.
  • Gastrin significantly increased endogenous CCK2R expression in RGM1 cells, and CCK2R protein expression was elevated in the stomach of hypergastrinaemic animals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Sep;283(3):G787-93 [12181195.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Feb;282(2):G359-66 [11804858.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):615-25 [12612900.001]
  • [Cites] Pancreatology. 2003;3(1):47-54 [12649564.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):510-21 [12891554.001]
  • [Cites] Am J Physiol. 1979 Sep;237(3):E284-94 [224710.001]
  • [Cites] Am J Physiol. 1980 Feb;238(2):G135-40 [6244744.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Nov;77(11):6917-21 [6256771.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3605-9 [1373504.001]
  • [Cites] Science. 1992 Dec 4;258(5088):1662-5 [1333642.001]
  • [Cites] Gastroenterology. 1993 Aug;105(2):449-61 [7687574.001]
  • [Cites] Ann N Y Acad Sci. 1994 Mar 23;713:283-97 [8185170.001]
  • [Cites] Science. 1994 Jul 15;265(5170):410-2 [8023165.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1019-30 [7926455.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2683-9 [8839863.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11825-30 [8876222.001]
  • [Cites] J Clin Invest. 1996 Oct 15;98(8):1918-29 [8878444.001]
  • [Cites] Am J Physiol. 1997 Jan;272(1 Pt 1):G161-71 [9038890.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1197-205 [9098003.001]
  • [Cites] Biochim Biophys Acta. 1997 Jul 25;1327(2):213-21 [9271263.001]
  • [Cites] J Biol Chem. 1997 Oct 24;272(43):27015-24 [9341140.001]
  • [Cites] Am J Physiol. 1998 Mar;274(3 Pt 1):G561-8 [9530158.001]
  • [Cites] Mol Psychiatry. 1999 May;4(3):284-5 [10395221.001]
  • [Cites] Am J Physiol. 1999 Jul;277(1 Pt 1):C1-9 [10409103.001]
  • [Cites] Pflugers Arch. 2005 Jan;449(4):344-55 [15480747.001]
  • [Cites] Rocz Akad Med Bialymst. 2005;50:21-36 [16358936.001]
  • [Cites] Gut. 2006 Feb;55(2):295-6 [16407391.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1169-80 [16618411.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1754-63 [16697739.001]
  • [Cites] Physiol Rev. 2006 Jul;86(3):805-47 [16816139.001]
  • [Cites] Oncogene. 2006 Jul 27;25(32):4421-8 [16547500.001]
  • [Cites] Lab Invest. 2006 Oct;86(10):1037-51 [16894354.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Apr;292(4):G1133-40 [17218472.001]
  • [Cites] Am J Pathol. 2007 Jun;170(6):1807-16 [17525249.001]
  • [Cites] Exp Physiol. 2007 Jul;92(4):591-601 [17412751.001]
  • [Cites] Gastroenterology. 1997 Sep;113(3):1015-25 [9287997.001]
  • [Cites] Pharmacol Rev. 1999 Dec;51(4):745-81 [10581329.001]
  • [Cites] Cell Tissue Res. 2000 Feb;299(2):289-98 [10741470.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 16;272(3):837-42 [10860839.001]
  • [Cites] J Clin Invest. 2000 Oct;106(8):1021-9 [11032862.001]
  • [Cites] Gut. 2000 Dec;47(6):762-70 [11076873.001]
  • [Cites] Mol Psychiatry. 2001 Jan;6(1):59-65 [11244486.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7661-71 [11113118.001]
  • [Cites] Regul Pept. 2001 Sep 15;101(1-3):25-33 [11495676.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):98-104 [11689954.001]
  • [Cites] Am J Med Genet. 2001 Dec 8;105(8):779-82 [11803530.001]
  • [Cites] Mol Endocrinol. 2002 Dec;16(12):2802-18 [12456801.001]
  • (PMID = 17933865.001).
  • [ISSN] 0958-0670
  • [Journal-full-title] Experimental physiology
  • [ISO-abbreviation] Exp. Physiol.
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / / 072501/Z/03
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Culture Media, Serum-Free; 0 / Gastrins; 0 / Receptor, Cholecystokinin B; 63231-63-0 / RNA
  • [Other-IDs] NLM/ PMC2253704
  •  go-up   go-down


76. Ribeiro HF, Alcântara DF, Matos LA, Sousa JM, Leal MF, Smith MA, Burbano RR, Bahia MO: Cytogenetic characterization and evaluation of c-MYC gene amplification in PG100, a new Brazilian gastric cancer cell line. Braz J Med Biol Res; 2010 Aug;43(8):717-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study characterized cytogenetically PG-100, the first commercially available gastric cancer cell line derived from a Brazilian patient who had a gastric adenocarcinoma, using GTG banding and fluorescent in situ hybridization to determine MYC amplification.
  • Eighty-six percent of 200 cells analyzed by fluorescent in situ hybridization presented MYC overexpression.


77. Höhler T, Rüschoff J, Ridwelski K, Moehler M: [HER2 testing and targeted therapy in advanced gastric cancer]. Onkologie; 2010;33 Suppl 4:26-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients whose tumors were either scored on immunohistochemistry (IHC) as 3+ (independently of the result of fluorescence in situ hybridization (FISH)) or as IHC2+ and FISH+ were found, in a planned subgroup analysis, to have a median overall survival time of 16.0 months--versus 11.8 months when trastuzumab was not given.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Drug Delivery Systems. Receptor, ErbB-2 / genetics. Stomach Neoplasms / drug therapy. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. Algorithms. Antibodies, Monoclonal, Humanized. Biopsy. Clinical Trials, Phase III as Topic. Drug Approval. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Multicenter Studies as Topic. Neoplasm Invasiveness. Neoplasm Staging. Practice Guidelines as Topic. Randomized Controlled Trials as Topic. Stomach / pathology. Survival Rate. Trastuzumab

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20431310.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


78. Trimeche M, Ksiâa F, Ziadi S, Mestiri S, Hachana M, Gacem RB, Sriha B, Korbi S: Prevalence and characteristics of Epstein-Barr virus-associated gastric carcinomas in Tunisia. Eur J Gastroenterol Hepatol; 2009 Sep;21(9):1001-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Ninety-six nonselected GC cases (male/female ratio 1.7/1, mean age 60.9 years, range: 20-88 years) were evaluated for the presence of EBV by polymerase chain reaction as well as by in-situ hybridization for EBV-encoded small RNAs (EBERs) and immunohistochemistry for LMP-1 and EBNA-2 expression.
  • [MeSH-major] Adenocarcinoma / pathology. Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human / isolation & purification. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19491698.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


79. Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH, Bokemeyer C, Izbicki JR, Sauter G: HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol; 2009 Jun;40(6):769-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address the potential applicability of trastuzumab in gastric cancer, tissue microarray sections of 166 gastric adenocarcinomas and 69 lymph node metastases were analyzed for Her-2 overexpression and amplification using Food and Drug Administration-approved reagents for immunohistochemistry and fluorescence in situ hybridization.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antigens, Neoplasm / genetics. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Lymphatic Metastasis. Male. Middle Aged. Receptor, ErbB-2 / immunology. Tissue Array Analysis. Trastuzumab

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2011 Jun;42(6):909-10; author reply 910-1 [21571126.001]
  • [CommentIn] Hum Pathol. 2010 Feb;41(2):304-5; author reply 305-6 [19914678.001]
  • (PMID = 19269014.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha; P188ANX8CK / Trastuzumab
  •  go-up   go-down


80. Baldus SE, Mönig SP, Zirbes TK, Thakran J, Köthe D, Köppel M, Hanisch FG, Thiele J, Schneider PM, Hölscher AH, Dienes HP: Lewis(y) antigen (CD174) and apoptosis in gastric and colorectal carcinomas: correlations with clinical and prognostic parameters. Histol Histopathol; 2006 05;21(5):503-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, we tried to elucidate its clinicopathological relevance in a series of 160 gastric and 215 colorectal carcinomas by immunohistochemical detection of Le(y) and visualization of apoptotic cells applying the in-situ-end labelling (ISEL) method, followed by semiquantitative scoring of the specimens.
  • Signet-ring cell carcinomas of the stomach exhibited a significantly stronger Le(y) expression compared to other tumor types.
  • [MeSH-major] Adenocarcinoma / immunology. Apoptosis. Carcinoma, Signet Ring Cell / immunology. Colorectal Neoplasms / immunology. Lewis Blood-Group System / analysis. Stomach Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16493580.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Lewis Blood-Group System; 0 / Lewis Y antigen
  •  go-up   go-down


81. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology; 2008 Jun;52(7):797-805
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: Formalin-fixed paraffin-embedded gastric cancer samples were tested for HER2 status using the fluorescence in situ hybridization (FISH) pharmDxt kit (Dako Denmark A/S).
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Receptor, ErbB-2 / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Consensus. Humans. Immunohistochemistry / methods. In Situ Hybridization, Fluorescence / methods. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18422971.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Number-of-references] 40
  •  go-up   go-down


82. Bouché O, Penault-Llorca F: [HER2 and gastric cancer: a novel therapeutic target for trastuzumab]. Bull Cancer; 2010 Dec;97(12):1429-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HER2 protein overexpression by immunohistochemistry (IHC) and/or erB2 gene amplification by in situ hybridization (ISH) was detected in 4-28% of gastric or gastro-oesophageal junction (GOJ) cancers.
  • Trastuzumab plus FP chemotherapy has become the standard treatment for patients with HER2+ non-pretreated metastatic adenocarcinoma of the stomach or GOJ cancer.
  • Equivocal IHC2+ tumours should be tested by ISH with two tools: fluorescence in situ hybridization (FISH) or bright field in situ hybridization (SISH).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Esophagogastric Junction. Receptor, ErbB-2 / analysis. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Capecitabine. Cisplatin / administration & dosage. Cisplatin / contraindications. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Immunohistochemistry / methods. In Situ Hybridization / methods. Paraffin Embedding. Randomized Controlled Trials as Topic. Trastuzumab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21134821.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


83. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol; 2005 Feb;16(2):273-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: The frequency of HER-2/neu and Topoisomerase IIalpha gene amplification was studied in adenocarcinomas of the stomach (n=131) and the gastroesophageal junction (n=100) by chromogenic in situ hybridization (CISH).
  • HER-2/neu amplification was more common in the intestinal histologic type of gastric cancer (21.5%) than in the diffuse (2%) or the mixed/anaplastic type (5%, P=0.0051), but it was not associated with gender, age at diagnosis or clinical stage.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15668283.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Isoenzymes; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


84. Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol; 2006 Oct 20;24(30):4922-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Patients with a histologically proven diagnosis of adenocarcinoma of the GEJ or stomach (ST) that was unresectable or metastatic; presence of measurable disease; no prior chemotherapy for advanced or metastatic cancer; Zubrod performance status (PS) of 0 to 1; and adequate renal, hepatic, and hematologic function were treated with erlotinib 150 mg/d orally.
  • No somatic mutations of the EGFR exons 18, 19, or 21 were detected and there was no gross amplification of EGFR by fluorescence in situ hybridization.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Esophageal Neoplasms / drug therapy. Esophagogastric Junction. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Mar 1;25(7):910; author reply 911 [17327617.001]
  • [ErratumIn] J Clin Oncol. 2007 Jun 1;25(16):2334
  • (PMID = 17050876.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA58658; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA58723; United States / NCI NIH HHS / CA / CA58882; United States / NCI NIH HHS / CA / CA63848; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA67663; United States / NCI NIH HHS / CA / CA76447; United States / NCI NIH HHS / CA / CA76448; United States / NCI NIH HHS / CA / CA86780
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride
  •  go-up   go-down


85. van Duin M, van Marion R, Watson JE, Paris PL, Lapuk A, Brown N, Oseroff VV, Albertson DG, Pinkel D, de Jong P, Nacheva EP, Dinjens W, van Dekken H, Collins C: Construction and application of a full-coverage, high-resolution, human chromosome 8q genomic microarray for comparative genomic hybridization. Cytometry A; 2005;63(1):10-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For validation of the array DNA samples of gastroesophageal and prostate cancer cell lines, and chronic myeloid leukemia specimens were used, which were previously characterized by multicolor fluorescence in situ hybridization and conventional CGH.
  • Single copy loss and high-level amplifications were accurately detected and confirmed by bicolor fluorescence in situ hybridization experiments.
  • [MeSH-minor] Adenocarcinoma / genetics. Cardia. Chromosome Aberrations. Fixatives. Formaldehyde. Humans. In Situ Hybridization, Fluorescence. Male. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis. Prostatic Neoplasms / genetics. Stomach Neoplasms / genetics. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15619731.001).
  • [ISSN] 1552-4922
  • [Journal-full-title] Cytometry. Part A : the journal of the International Society for Analytical Cytology
  • [ISO-abbreviation] Cytometry A
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA89520
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fixatives; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


86. Morikawa T, Hino R, Uozaki H, Maeda D, Ushiku T, Shinozaki A, Sakatani T, Fukayama M: Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro. Hum Pathol; 2010 Dec;41(12):1742-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / enzymology. Enzyme Inhibitors / pharmacology. Ribonucleoside Diphosphate Reductase / antagonists & inhibitors. Ribonucleoside Diphosphate Reductase / metabolism. Stomach Neoplasms / enzymology
  • [MeSH-minor] Cell Line, Tumor. Cell Survival. Epstein-Barr Virus Infections. Female. Gastric Mucosa. Gene Silencing. Herpesvirus 4, Human / isolation & purification. Humans. Immunohistochemistry. In Situ Hybridization. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Staging. RNA, Small Interfering / genetics. Tissue Array Analysis. Transfection

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20825972.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / RNA, Small Interfering; EC 1.17.4.- / ribonucleotide reductase M2; EC 1.17.4.1 / Ribonucleoside Diphosphate Reductase
  •  go-up   go-down


87. Lee JH, Byun DS, Lee MG, Ryu BK, Kang MJ, Chae KS, Lee KY, Kim HJ, Park H, Chi SG: Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses. Int J Cancer; 2008 Apr 1;122(7):1573-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Gene Silencing. Intracellular Signaling Peptides and Proteins / genetics. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenoma / genetics. Apoptosis. Blotting, Northern. Cell Line, Tumor. CpG Islands / genetics. DNA Methylation. Down-Regulation. Flow Cytometry. Fluorescent Antibody Technique. Hamartoma / genetics. Humans. Immunoblotting. In Situ Nick-End Labeling. Neoplastic Stem Cells. Polyps / genetics. Promoter Regions, Genetic / genetics. Reverse Transcriptase Polymerase Chain Reaction. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18059034.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / PRKCDBP protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


88. Leal MF, Martins do Nascimento JL, da Silva CE, Vita Lamarão MF, Calcagno DQ, Khayat AS, Assumpção PP, Cabral IR, de Arruda Cardoso Smith M, Burbano RR: Establishment and conventional cytogenetic characterization of three gastric cancer cell lines. Cancer Genet Cytogenet; 2009 Nov;195(1):85-91
Cellosaurus - a cell line knowledge resource. culture/stock collections - AGP01 (CVCL_IK53) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we describe the establishment and cytogenetic characterization of three new gastric cancer cell lines obtained from primary gastric adenocarcinoma (ACP02 and ACP03) and cancerous ascitic fluid (AGP01) of individuals from northern Brazil.
  • Chromosome 8 aneusomy was confirmed by fluorescence in situ hybridization.
  • [MeSH-major] Adenocarcinoma / genetics. Cell Line, Tumor. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - ACP02 (CVCL_IK51) .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - ACP03 (CVCL_IK52) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19837275.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


89. Hou Q, Wu YH, Grabsch H, Zhu Y, Leong SH, Ganesan K, Cross D, Tan LK, Tao J, Gopalakrishnan V, Tang BL, Kon OL, Tan P: Integrative genomics identifies RAB23 as an invasion mediator gene in diffuse-type gastric cancer. Cancer Res; 2008 Jun 15;68(12):4623-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RAB23 amplifications in primary gastric tumors were confirmed by both fluorescence in situ hybridization and genomic qPCR, and in two independent patient cohorts from Hong Kong and the United Kingdom RAB23 expression was significantly associated with diffuse-type GC (dGC) compared with intestinal-type GC (iGC).
  • [MeSH-major] Chromosomes, Human, Pair 6 / genetics. Polymorphism, Single Nucleotide / genetics. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology. rab GTP-Binding Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Movement. Chromosome Mapping. Chromosomes, Artificial, Bacterial. Cohort Studies. Female. Gene Amplification. Gene Dosage. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genomics. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18559507.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 3.6.1.- / RAB23 protein, human; EC 3.6.1.- / rab GTP-Binding Proteins
  •  go-up   go-down


90. Truong CD, Feng W, Li W, Khoury T, Li Q, Alrawi S, Yu Y, Xie K, Yao J, Tan D: Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in U.S.A. J Exp Clin Cancer Res; 2009;28:14
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Formalin-fixed paraffin-embedded tissue from these resection specimens were assessed for EBV by in situ hybridization, the gold standard for EBV detection in tissue.
  • [MeSH-major] Adenocarcinoma / virology. Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human / isolation & purification. Stomach Neoplasms / virology. Tumor Virus Infections / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Gastric Mucosa / virology. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. RNA, Viral / biosynthesis. Retrospective Studies. Risk Factors. United States. Viral Matrix Proteins / biosynthesis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1991 Sep;139(3):469-74 [1653517.001]
  • [Cites] World J Gastroenterol. 2005 Oct 21;11(39):6096-103 [16273633.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1063-71 [8214002.001]
  • [Cites] Am J Pathol. 1993 Nov;143(5):1250-4 [8238241.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):805-9 [8039108.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9131-5 [8090780.001]
  • [Cites] Histopathology. 1994 Oct;25(4):323-9 [7835837.001]
  • [Cites] Hum Pathol. 1996 Jan;27(1):20-7 [8543306.001]
  • [Cites] J Pathol. 1997 Nov;183(3):293-8 [9422984.001]
  • [Cites] J Clin Gastroenterol. 1999 Jul;29(1):39-43 [10405229.001]
  • [Cites] World J Gastroenterol. 2005 Feb 7;11(5):629-33 [15655811.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2745-8 [10825150.001]
  • [Cites] Pathol Int. 2000 Jun;50(6):486-92 [10886725.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):255-61 [11091849.001]
  • [Cites] J Med Virol. 2001 Aug;64(4):513-8 [11468737.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):612-8 [11522745.001]
  • [Cites] J Med Virol. 2002 Mar;66(3):351-9 [11793387.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Jan;45(1):1-36 [12482570.001]
  • [Cites] J Pathol. 2003 Feb;199(2):140-5 [12533825.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):597-604 [12827614.001]
  • [Cites] Gastric Cancer. 2003;6(3):173-8 [14520531.001]
  • [Cites] Cancer Lett. 2003 Oct 8;200(1):33-40 [14550950.001]
  • [Cites] Diagn Mol Pathol. 2003 Dec;12(4):201-11 [14639106.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):664-70 [14966089.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):430-9 [14739904.001]
  • [Cites] J Clin Pathol. 2004 May;57(5):487-91 [15113855.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3218-29 [15249585.001]
  • [Cites] Mod Pathol. 1990 May;3(3):377-80 [2163534.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):769-74 [1314023.001]
  • (PMID = 19192297.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / RNA, Viral; 0 / Viral Matrix Proteins
  • [Other-IDs] NLM/ PMC2642773
  •  go-up   go-down


91. Wang LL, Yao GY, Zhang BY, Zhang XM, Zhao M: [Expression and significance of CD147 and E-cadherin in human gastric carcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Jul;31(7):515-9
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expression of CD147 and E-cadherin in gastric cancer tissue chip (TC) was detected by in situ hybridization (ISH) and immunohistochemistry in 220 cases of gastric carcinoma and 31 cases with normal gastric mucosa.
  • [MeSH-major] Adenocarcinoma, Papillary / metabolism. Antigens, CD147 / metabolism. Biomarkers, Tumor / metabolism. Cadherins / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Staging. RNA, Messenger / metabolism. Survival Rate. Tumor Burden

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950699.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BSG protein, human; 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / RNA, Messenger; 136894-56-9 / Antigens, CD147
  •  go-up   go-down


92. Moon WS, Park HS, Yu KH, Jang KY, Kang MJ, Park H, Tarnawski AS: Expression of angiopoietin 1, 2 and their common receptor Tie2 in human gastric carcinoma: implication for angiogenesis. J Korean Med Sci; 2006 Apr;21(2):272-8
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined expression of Ang-1, Ang-2, and their common receptor Tie2 mRNAs and proteins in gastric cancers using in situ hybridization and immunohistochemistry.
  • [MeSH-major] Angiopoietin-1 / genetics. Angiopoietin-1 / metabolism. Angiopoietin-2 / genetics. Angiopoietin-2 / metabolism. Receptor, TIE-2 / genetics. Receptor, TIE-2 / metabolism. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / blood supply. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Signet Ring Cell / blood supply. Carcinoma, Signet Ring Cell / genetics. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Female. Gene Expression. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Neovascularization, Pathologic. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Oct 15;86(8):1455-62 [10526273.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):213-23 [10068209.001]
  • [Cites] Br J Cancer. 2000 Nov;83(9):1154-60 [11027428.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1255-9 [11245414.001]
  • [Cites] Pathol Res Pract. 2001;197(2):101-7 [11261813.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2145-53 [11280779.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):918-27 [11309342.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):5217-20 [11326698.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5736-40 [11479209.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):651-9 [11485923.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6248-54 [11507079.001]
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):6-15 [11668472.001]
  • [Cites] Leuk Res. 2002 Feb;26(2):163-8 [11755466.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7124-9 [12460935.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):552-7 [12808060.001]
  • [Cites] Blood Cells Mol Dis. 2004 Jan-Feb;32(1):168-75 [14757432.001]
  • [Cites] Histopathology. 2004 Mar;44(3):232-9 [14987226.001]
  • [Cites] J Hepatol. 2004 May;40(5):799-807 [15094228.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1557-70 [15509526.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):598-603 [1311287.001]
  • [Cites] Oncogene. 1993 May;8(5):1293-301 [8386827.001]
  • [Cites] Growth Factors. 1993;9(2):99-105 [8217221.001]
  • [Cites] J Pathol. 1996 Jul;179(3):232-7 [8774475.001]
  • [Cites] Cell. 1996 Dec 27;87(7):1161-9 [8980223.001]
  • [Cites] Cell. 1996 Dec 27;87(7):1171-80 [8980224.001]
  • [Cites] Science. 1997 Jul 4;277(5322):55-60 [9204896.001]
  • [Cites] Int J Cancer. 1997 Oct 21;74(5):545-50 [9355979.001]
  • [Cites] Science. 1998 Oct 16;282(5388):468-71 [9774272.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):594-9 [9778629.001]
  • [Cites] J Clin Invest. 2000 Aug;106(4):511-21 [10953026.001]
  • (PMID = 16614513.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / ANGPT1 protein, human; 0 / Angiopoietin-1; 0 / Angiopoietin-2; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.10.1 / Receptor, TIE-2
  • [Other-IDs] NLM/ PMC2734003
  •  go-up   go-down


93. Barros-Silva JD, Leitão D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Rêgo S, Brandão C, Carneiro F, Lopes C, Schmitt F, Teixeira MR: Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer; 2009 Feb 10;100(3):487-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we evaluated the ERBB2 status in 463 gastric carcinomas using immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH), and compared the findings with histopathological characteristics and with disease-specific survival.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-2. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cross-Sectional Studies. Gene Amplification. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1989 Apr;4(3):362-6 [2565881.001]
  • [Cites] Oncogene. 1989 Jan;4(1):81-8 [2563577.001]
  • [Cites] Hum Pathol. 1990 Mar;21(3):325-32 [2312109.001]
  • [Cites] Mod Pathol. 1992 Jul;5(4):384-90 [1353880.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3942-6 [8099528.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3845-52 [8033105.001]
  • [Cites] Int Surg. 1994 Jan-Mar;79(1):27-32 [8063551.001]
  • [Cites] Oncogene. 1997 Jul 31;15(5):537-47 [9247307.001]
  • [Cites] Lab Invest. 1998 Mar;78(3):345-51 [9520947.001]
  • [Cites] J Gastrointest Surg. 1998 Mar-Apr;2(2):126-31 [9834407.001]
  • [Cites] Cancer. 1999 May 1;85(9):1894-902 [10223227.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2241-51 [10327070.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):255-62 [15517369.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):273-8 [15668283.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Breast Cancer. 2005 Aug;6(3):240-6 [16137435.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] World J Surg. 2005 Nov;29(11):1422-7; discussion 1428 [16222448.001]
  • [Cites] Gastric Cancer. 2005;8(4):249-52 [16328600.001]
  • [Cites] Dig Dis Sci. 2006 Aug;51(8):1371-9 [16868827.001]
  • [Cites] Mol Syst Biol. 2006;2:54 [17016520.001]
  • [Cites] Cell Oncol. 2006;28(5-6):283-94 [17167181.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1386-93 [17555797.001]
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] Eur J Cancer. 2000 Feb;36(3):390-6 [10708942.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):16-7 [10973239.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):837-43 [10997811.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3651-64 [11054438.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):556-62 [11406656.001]
  • [Cites] Acta Oncol. 2001;40(2-3):309-26 [11441938.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1178-80 [11583204.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):84-9 [11823704.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):833-7 [11948459.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):1023-8 [12439918.001]
  • [Cites] J Pathol. 2003 Apr;199(4):418-23 [12635131.001]
  • [Cites] Eur J Surg. 2002;168(11):597-608 [12699095.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):548-53 [14991576.001]
  • [Cites] Cancer. 1977 Jun;39(6):2475-85 [872047.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Dec;81(23):7308-12 [6095284.001]
  • [Cites] Science. 1986 Jun 27;232(4758):1644-6 [3012781.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • (PMID = 19156142.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2658544
  •  go-up   go-down


94. Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, Park K, Nam SW, Park WS, Kim SH, Lee JY, Yoo NJ, Lee SH: Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res; 2006 Jan 1;12(1):57-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Recent reports revealed that the kinase domain of the ERBB2 gene is somatically mutated in lung adenocarcinoma, suggesting the mutated ERBB2 gene as an oncogene in human cancers.
  • [MeSH-major] Breast Neoplasms / genetics. Colorectal Neoplasms / genetics. Genes, erbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. DNA Mutational Analysis. Female. Genes, ras / genetics. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Phosphatidylinositol 3-Kinases / genetics. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Proto-Oncogene Proteins B-raf / genetics. Receptor, Epidermal Growth Factor / genetics


95. Park JH, Lee BL, Yoon J, Kim J, Kim MA, Yang HK, Kim WH: Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer. Hum Pathol; 2010 Dec;41(12):1664-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regarding focal adhesion kinase gene amplification, fluorescence in situ hybridization analysis showed focal adhesion kinase gene amplification in 34 (8.9%) of 384 gastric cancer specimens, whereas there was no amplification in any case of atrophy, intestinal metaplasia, or adenoma/dysplasia.
  • Thus, focal adhesion kinase gene amplification could supplement its protein expression for the diagnosis and treatment of gastric cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Focal Adhesion Kinase 1 / genetics. Gene Amplification. Stomach Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Cell Membrane / enzymology. Cell Membrane / pathology. Cytoplasm / enzymology. Cytoplasm / pathology. DNA, Neoplasm / analysis. Disease Progression. Female. Humans. In Situ Hybridization, Fluorescence. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis. Republic of Korea / epidemiology. Survival Rate. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20869748.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.10.2 / PTK2 protein, human
  •  go-up   go-down


96. Wang GR, Zheng Y, Che XM, Wang XQ, Wang XW, Pan CE, He WX: [Expression of heparin-binding epidermal growth factor-like growth factor in patients with gastric carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jan;29(1):44-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expressions of HB-EGF protein and mRNA in normal gastric tissues, metaplasic intestinal mucosa, early-stage gastric cancer and advanced-stage gastric cancer tissues were detected by immunohistochemistry and in situ hybridization.
  • [MeSH-major] Adenocarcinoma / metabolism. Intercellular Signaling Peptides and Proteins / metabolism. Stomach Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19218109.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HBEGF protein, human; 0 / Heparin-binding EGF-like Growth Factor; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger
  •  go-up   go-down


97. Luo B, Wang Y, Wang XF, Liang H, Yan LP, Huang BH, Zhao P: Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas. World J Gastroenterol; 2005 Feb 7;11(5):629-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EBV-encoded small RNA (EBER) 1 of the PCR positive specimens was detected by in situ hybridization (ISH).
  • [MeSH-major] Adenocarcinoma / virology. Epstein-Barr Virus Infections / genetics. Gene Expression Regulation, Neoplastic. Gene Expression Regulation, Viral. Herpesvirus 4, Human / genetics. Stomach Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655811.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4250728
  •  go-up   go-down


98. Mózsik G, Rumi G, Dömötör A, Figler M, Gasztonyi B, Papp E, Pár A, Pár G, Belágyi J, Matus Z, Melegh B: Involvement of serum retinoids and Leiden mutation in patients with esophageal, gastric, liver, pancreatic, and colorectal cancers in Hungary. World J Gastroenterol; 2005 Dec 28;11(48):7646-50
Hazardous Substances Data Bank. BETA-CAROTENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The changes in serum levels of retinoids (vitamin A, alpha- and beta-carotene, alpha- and beta-cryptoxanthin, zeaxanthin, lutein) and Leiden mutation were measured by high liquid performance chromatography (HPLC) and polymerase chain reaction (PCR) in 107 patients (70 males/37 females) with esophageal (0/8), gastric (16/5), liver (8/7), pancreatic (6/4), and colorectal (30/21 including 9 patients suffering from in situ colon cancer) cancer.
  • CONCLUSION: Retinoids (as environmental factors) are decreased significantly with increased prevalence of Leiden mutation (as a genetic factor) in patients before the clinical manifestation of histologically different (planocellular and hepatocellular carcinoma, and adenocarcinoma) GI cancer.
  • [MeSH-major] Colorectal Neoplasms / blood. Esophageal Neoplasms / blood. Factor V / genetics. Liver Neoplasms / blood. Pancreatic Neoplasms / blood. Point Mutation. Retinoids / blood. Stomach Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. VITAMIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437692.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Retinoids; 0 / Xanthophylls; 0 / Zeaxanthins; 0 / factor V Leiden; 01YAE03M7J / beta Carotene; 11103-57-4 / Vitamin A; 9001-24-5 / Factor V
  • [Other-IDs] NLM/ PMC4727222
  •  go-up   go-down


99. Soini Y, Tommola S, Helin H, Martikainen P: Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virchows Arch; 2006 Jan;448(1):52-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Membrane Proteins / biosynthesis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology
  • [MeSH-minor] Apoptosis / physiology. Biomarkers, Tumor / analysis. Cadherins / biosynthesis. Cell Proliferation. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Ki-67 Antigen / biosynthesis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16220299.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Ki-67 Antigen; 0 / Membrane Proteins
  •  go-up   go-down


100. Kim J, Kim MA, Jee CD, Jung EJ, Kim WH: Reduced expression and homozygous deletion of annexin A10 in gastric carcinoma. Int J Cancer; 2009 Oct 15;125(8):1842-50
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Annexins / genetics. Gene Deletion. Homozygote. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Apoptosis. Blotting, Western. Case-Control Studies. Cell Movement. Cell Proliferation. Cells, Cultured. Chromosome Mapping. Chromosomes, Human, Pair 4 / genetics. Colony-Forming Units Assay. Comparative Genomic Hybridization. Female. Gene Expression Profiling. Humans. Immunoblotting. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Kidney / embryology. Kidney / metabolism. Kidney / pathology. Lymphatic Metastasis. Male. Mutation / genetics. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Stomach / metabolism. Stomach / pathology. Tissue Array Analysis. Tumor Cells, Cultured. Wound Healing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19582876.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ANXA10 protein, human; 0 / Annexins; 0 / RNA, Messenger; 0 / RNA, Small Interfering
  •  go-up   go-down






Advertisement